PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrNUCALA

Mepolizumab for Injection
100 mg/mL lyophilized powder for subcutaneous injection

Mepolizumab Injection
100 mg/mL solution for subcutaneous injection

Interleukin-5 (IL-5) inhibitor

GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4

Date of Initial Approval:
April 6, 2016

Date of Revision:
March 12, 2020

Submission Control No.: 226197

© 2020 GSK group of companies or its licensor
Trademarks are owned by or licensed to the GSK group of companies
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION .................................................................3
  SUMMARY PRODUCT INFORMATION ........................................................................3
  DESCRIPTION ................................................................................................................3
  INDICATIONS AND CLINICAL USE ..........................................................................3
  CONTRAINDICATIONS ................................................................................................4
  WARNINGS AND PRECAUTIONS ..............................................................................4
  ADVERSE REACTIONS ...............................................................................................6
  DRUG INTERACTIONS ................................................................................................18
  DOSAGE AND ADMINISTRATION ...........................................................................18
  OVERDOSAGE ...........................................................................................................23
  ACTION AND CLINICAL PHARMACOLOGY ...........................................................23
  STORAGE AND STABILITY ......................................................................................26
  SPECIAL HANDLING INSTRUCTIONS .................................................................27
  DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................27

PART II: SCIENTIFIC INFORMATION .............................................................................28
  PHARMACEUTICAL INFORMATION ......................................................................28
  CLINICAL TRIALS .....................................................................................................29
  TOXICOLOGY ............................................................................................................40
  REFERENCES .............................................................................................................41

PATIENT MEDICATION INFORMATION (Lyophilized Powder) ....................................42

PATIENT MEDICATION INFORMATION (Autoinjector & Safety Syringe) .....................49

INSTRUCTIONS FOR USE – Pre-Filled Autoinjector .....................................................56

INSTRUCTIONS FOR USE – Pre-Filled Safety Syringe ................................................63
**PrNUCALA**

**Mepolizumab for Injection**

**and**

**Mepolizumab Injection**

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>By subcutaneous injection.</td>
<td>Lyophilized powder for subcutaneous injection. Each single-use vial contains 100 mg/mL mepolizumab after reconstitution.</td>
<td>No clinically relevant nonmedicinal ingredients. For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</td>
</tr>
<tr>
<td></td>
<td>Solution for subcutaneous injection. Each single-use pre-filled autoinjector or safety syringe contains 100 mg/mL mepolizumab.</td>
<td></td>
</tr>
</tbody>
</table>

DESCRIPTION

NUCALA (mepolizumab for injection and mepolizumab injection) is a humanised IgG1 kappa monoclonal antibody that binds with high affinity and specificity to soluble interleukin-5 (IL-5). Mepolizumab has a molecular weight of approximately 149 kDa and is produced by recombinant DNA technology in Chinese hamster ovary cells.

INDICATIONS AND CLINICAL USE

**Severe Eosinophilic Asthma**

NUCALA is indicated as add-on maintenance treatment for adults, adolescents, and children (aged 6 years and older) with severe eosinophilic asthma who:

- are inadequately controlled with high-dose inhaled corticosteroids (patients ≥ 18 years of age) or medium-to-high-dose inhaled corticosteroids (patients 6-17 years of age) and an additional asthma controller(s) (e.g., LABA); and

- have a blood eosinophil count of ≥ 150 cells/μL (0.15 GI/L) at initiation of treatment with NUCALA OR ≥ 300 cells/μL (0.3 GI/L) in the past 12 months.
NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus (See WARNINGS AND PRECAUTIONS).

Eosinophilic Granulomatosis with Polyangiitis

NUCALA is indicated as an add-on to corticosteroids for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Pediatrics (< 18 years of age):

Severe Eosinophilic Asthma: NUCALA is not indicated in patients under 6 years of age. There is limited efficacy and safety experience with NUCALA in patients less than 18 years of age (see CLINICAL TRIALS, Severe Eosinophilic Asthma).

Dosing in children was derived using modelling and simulation of adult and pediatric PK data (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Patient Populations).

Eosinophilic Granulomatosis with Polyangiitis: NUCALA is not indicated in patients under 18 years of age.

Geriatrics (≥ 65 years of age):

There is limited efficacy and safety experience with NUCALA in patients over 65 years of age (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Patient Populations).

CONTRAINDICATIONS

NUCALA is contraindicated in patients who are hypersensitive to mepolizumab, to any ingredient(s) in the formulations, or component(s) of the containers. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING.

WARNINGS AND PRECAUTIONS

General

Hypersensitivity and Administration-Related Reactions

Acute and delayed systemic reactions, including hypersensitivity reactions (e.g., anaphylaxis, urticaria, angioedema, rash, bronchospasm, hypotension), have occurred following administration of NUCALA. These reactions generally occur within hours of administration, but in some instances had a delayed onset (i.e., days). These reactions may occur for the first time after a long duration of treatment.
Acute Asthma Symptoms or Deteriorating Disease

NUCALA should not be used to treat acute asthma exacerbations.

Asthma-related adverse events or exacerbations may occur during treatment with NUCALA. Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.

Corticosteroid Reduction
Abrupt discontinuation of corticosteroids after initiation of NUCALA therapy is not recommended. Reductions in corticosteroid doses, if required, should be gradual and performed under the supervision of a physician.

Parasitic Infections
Eosinophils may be involved in the immunological response to some helminth infections. Patients with pre-existing helminth infections were excluded from participation in the clinical program. Patients with pre-existing helminth infections should be treated for their infection prior to initiating therapy with NUCALA. If patients become infected whilst receiving treatment with NUCALA and do not respond to recommended anti-helminth treatment, temporary discontinuation of NUCALA should be considered.

Opportunistic Infection by Herpes Zoster
In controlled clinical trials, two serious adverse reactions of herpes zoster occurred in subjects treated with NUCALA compared with 1 in placebo (see ADVERSE REACTIONS). Consider varicella vaccination if medically appropriate prior to starting therapy with NUCALA.

Special Populations

Pregnant Women: No studies have been conducted with NUCALA in pregnant women, and there are no fertility data in humans (see TOXICOLOGY). In clinical trials there were too few pregnancies reported to inform on maternal and fetal health and development outcomes.

NUCALA should not be used by pregnant women, unless the expected benefit to the mother justifies the potential risk to the fetus. Women should be advised to contact their physicians if they become pregnant while receiving NUCALA, or during the 4 months after treatment is stopped.

Pregnancy Registry
To monitor maternal-fetal outcomes of pregnant women with severe eosinophilic asthma exposed to NUCALA, a pregnancy registry has been established. Healthcare professionals are encouraged to register patients, and pregnant women are encouraged to enroll themselves by calling 1-877-311-8972 or visiting http://mothertobaby.org/asthma.

Nursing Women: There are no data regarding the presence of mepolizumab in human milk, the effects on the breastfed infant, or the effects on milk production (see TOXICOLOGY).
A decision should be made whether to discontinue breast-feeding or discontinue NUCALA, taking into account the importance of breast-feeding to the infant and the importance of the drug to the mother.

**Pediatrics (< 18 years of age):**
Patients less than 6 years of age were not included in the severe eosinophilic asthma clinical trials with NUCALA. There is limited efficacy and safety experience with NUCALA in pediatric patients less than 18 years of age. A total of 28/1327 (2.1%) patients age 12 to 17 years old were enrolled in the placebo-controlled severe asthma clinical trials with NUCALA; and 36 patients age 6 to 11 years old were enrolled in the uncontrolled severe asthma clinical trial with NUCALA.

Patients less than 18 years of age were not included in the eosinophilic granulomatosis with polyangiitis clinical trial with NUCALA.

**Geriatrics (≥ 65 years of age):**
There is limited efficacy and safety experience with NUCALA in patients over 65 years of age. A total of 119/1,327 (9.0%) patients age 65 and older were enrolled in the placebo-controlled severe asthma clinical trials with NUCALA. A total of 17/136 (13%) patients age 65 and older were enrolled in the eosinophilic granulomatosis with polyangiitis clinical trial with NUCALA. No dosage adjustment is required in patients 65 years or older (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Patient Populations).

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**

In clinical studies that enrolled adult and adolescent patients with severe eosinophilic asthma, the most commonly reported adverse drug reactions (events considered to be possibly related to treatment with mepolizumab) during treatment with NUCALA were headache, injection site reaction, and back pain. In a clinical study that enrolled children with severe eosinophilic asthma, the most commonly reported adverse drug reactions were headache, injection site reaction, abdominal pain upper, eczema, and pharyngitis.

In a clinical study that enrolled adult patients with eosinophilic granulomatosis with polyangiitis, the most commonly reported adverse drug reaction during treatment with NUCALA was headache.

Hypersensitivity reactions, including anaphylaxis, swelling of the face, mouth, and/or tongue; fainting, dizziness, or lightheadedness; hives; breathing problems; and rash have been reported within hours or days of receiving treatment with NUCALA.
Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Severe Eosinophilic Asthma

Adults and Adolescents (≥ 12 years of age)

The safety of mepolizumab has been studied in three randomized, placebo-controlled, multicentre clinical trials of 24 to 52 weeks duration and three open-label, uncontrolled, extension studies with a median treatment duration of 2.8 years (range 4 weeks to 4.5 years). A total of 1,327 adult and adolescent patients with severe eosinophilic asthma received either a subcutaneous (SC) dose or an intravenous (IV) dose of mepolizumab or placebo during randomized controlled trials. The safety profile was comparable between groups that received mepolizumab SC (NUCALA 100 mg) or IV (75 mg, 250 mg and 750 mg).

Two of the three placebo-controlled studies (MEA115588 and MEA115575) included NUCALA 100 mg SC. Adverse events from the placebo-controlled studies that were reported by 1% or more of patients with NUCALA 100 mg SC and that were reported more frequently than placebo (≥1% difference from placebo) are presented in Table 1.
Table 1: On-treatment Adverse Events with ≥1% incidence with NUCALA and ≥1% more common with NUCALA than placebo in adult and adolescent subjects with severe eosinophilic asthma from placebo-controlled studies (MEA115588 and MEA115575)

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>NUCALA 100 mg SC (N = 263) n (%)</th>
<th>Placebo (N = 257) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lacrimation increased</td>
<td>4 (1.5%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastroesophageal reflux disease</td>
<td>8 (3.0%)</td>
<td>3 (1.2%)</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>4 (1.5%)</td>
<td>0</td>
</tr>
<tr>
<td>Gastrointestinal disorder</td>
<td>3 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site reaction(^2)</td>
<td>21 (8.0%)</td>
<td>8 (3.1%)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>5 (1.9%)</td>
<td>2 (0.8%)</td>
</tr>
<tr>
<td>Local swelling</td>
<td>3 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>10 (3.8%)</td>
<td>5 (1.9%)</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>7 (2.7%)</td>
<td>4 (1.6%)</td>
</tr>
<tr>
<td><strong>Injury, poisoning and procedural complications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ligament sprain</td>
<td>3 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>16 (6.1%)</td>
<td>13 (5.1%)</td>
</tr>
<tr>
<td>Back pain</td>
<td>16 (6.1%)</td>
<td>9 (3.5%)</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>7 (2.7%)</td>
<td>1 (0.4%)</td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
<td>4 (1.5%)</td>
<td>1 (0.4%)</td>
</tr>
<tr>
<td>Neck pain</td>
<td>4 (1.5%)</td>
<td>0</td>
</tr>
<tr>
<td>Musculoskeletal stiffness</td>
<td>3 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td>Tendonitis</td>
<td>3 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>53 (20.2%)</td>
<td>47 (18.3%)</td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>7 (2.7%)</td>
<td>3 (1.2%)</td>
</tr>
<tr>
<td><strong>Reproductive system and breast disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysmenorrhoea</td>
<td>3 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>7 (2.7%)</td>
<td>2 (0.8%)</td>
</tr>
<tr>
<td>Rhinorrhoea</td>
<td>5 (1.9%)</td>
<td>1 (0.4%)</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eczema</td>
<td>11 (4.2%)</td>
<td>2 (0.8%)</td>
</tr>
</tbody>
</table>

\(^1\) MedDRA Version 16.1

\(^2\) The most common symptoms associated with subcutaneous injections included: pain, erythema, swelling, itching, and burning sensation.

Adverse drug reactions in adult and adolescent patients (events considered to be possibly related to treatment with mepolizumab) were identified following evaluation of all data from the three
randomized placebo-controlled trials and include: headache (very common; ≥1/10) and pharyngitis, lower respiratory tract infection, urinary tract infection, nasal congestion, upper abdominal pain, eczema, back pain, pyrexia, and injection site reactions (all common; ≥1/100 to <1/10).

The safety profile of NUCALA in a select subset of adult and adolescent subjects with severe eosinophilic asthma (n=998) who were tolerant to NUCALA and entered the open-label, uncontrolled, extension studies, and were treated with NUCALA 100mg SC every 4 weeks for a median of 2.8 years (range 4 weeks to 4.5 years), was consistent to that observed in the placebo-controlled studies.

**Pediatric Population (6 to 17 years of age)**

The safety of mepolizumab in adolescents (12-17 years of age) with severe eosinophilic asthma has been studied in 37 patients enrolled in four placebo-controlled studies, including 27 enrolled in two of these studies (MEA115588 and MEA115575); safety data from these 27 adolescent patients are presented within the adult and adolescent dataset above.

The safety of mepolizumab in children (6 to 11 years of age) with severe eosinophilic asthma has been studied in 36 patients in an uncontrolled, open-label study (200363). Patients received NUCALA 40 mg SC (for a weight <40 kg) or 100 mg SC (for a weight ≥40 kg) once every 4 weeks, for 12 weeks (short-term phase). After a treatment interruption of 8 weeks, 30 children resumed NUCALA treatment for a further 52 weeks (long-term phase). No additional adverse reactions were reported in children treated with NUCALA compared to those reported in adult and adolescent patients enrolled in the severe asthma trials. Adverse events from this study that were reported in more than 1 patient receiving NUCALA are presented in Table 2.
Table 2  On-treatment Adverse Events, occurring in >1 child (6-11 years of age) with severe eosinophilic asthma (Study 200363)

<table>
<thead>
<tr>
<th>Adverse Events¹</th>
<th>Short-Term Phase (12 weeks)</th>
<th>Long-Term Phase (52 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NUCALA SC (N=36) n (%)</td>
<td>Adverse Events²</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>3 (8)</td>
<td>Abdominal pain upper</td>
</tr>
<tr>
<td>Constipation</td>
<td>2 (6)</td>
<td>Constipation</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2 (6)</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site reaction</td>
<td>5 (14)</td>
<td>Pyrexia</td>
</tr>
<tr>
<td>Pain</td>
<td>2 (6)</td>
<td>-</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>4 (11)</td>
<td>Bronchitis</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>3 (8)</td>
<td>Nasopharyngitis</td>
</tr>
<tr>
<td>Lower respiratory tract infection</td>
<td>2 (6)</td>
<td>Upper respiratory tract infection</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>2 (6)</td>
<td>Influenza</td>
</tr>
<tr>
<td>Viral upper respiratory tract infection</td>
<td>2 (6)</td>
<td>Pharyngitis</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Viral upper respiratory tract infection</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Conjunctivitis</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Ear infection</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Gastroenteritis</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Impetigo</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Lower respiratory tract infection</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Rhinitis</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Back pain</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>5 (14)</td>
<td>Headache</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2 (6)</td>
<td>-</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Aggression</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>4 (11)</td>
<td>Asthma</td>
</tr>
<tr>
<td>Wheezing</td>
<td>3 (8)</td>
<td>Cough</td>
</tr>
<tr>
<td>Oropharyngeal pain</td>
<td>2 (6)</td>
<td>Epistaxis</td>
</tr>
<tr>
<td>Pharyngeal erythema</td>
<td>2 (6)</td>
<td>-</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>2 (6)</td>
<td>Eczema</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Dermatitis atopic</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Rash</td>
</tr>
</tbody>
</table>

¹ MedDRA Version 19.1
² MedDRA Version 20.1
Supplemental Adverse Event Information

The adult and adolescent data summarized below are from three completed placebo-controlled randomized clinical trials of 24 to 52 weeks duration that enrolled subjects with severe eosinophilic asthma who received either mepolizumab (NUCALA 100 mg SC or mepolizumab 75, 250 or 750 mg IV) or placebo. Data are presented for both the NUCALA (100 mg SC) treatment group and for all subjects receiving any dose of mepolizumab (referred to as the ‘mepolizumab all doses combined’ treatment group). Additionally, data from children (6 to 11 years of age) are presented for study 200363.

Fatalities

In placebo-controlled studies that enrolled adults and adolescents, 5 subjects died: 3 subjects (<1%) receiving mepolizumab (severe acute pancreatitis and septic shock in 1 subject receiving 250 mg IV; asthma in 1 subject receiving 250 mg IV; asphyxia due to suicide in 1 subject receiving 750 mg IV) and 2 subjects (<1%) receiving placebo (road traffic accident; aspiration and gastrointestinal hemorrhage). None of the deaths were considered related to study medication by the investigator.

There were no deaths reported in children receiving NUCALA from study 200363.

Serious Adverse Events

In placebo-controlled studies that enrolled adults and adolescents, serious adverse events were reported in 6% of subjects receiving NUCALA, 10% of subjects in the ‘mepolizumab all doses combined’ group, and 15% of subjects receiving placebo. Serious adverse events of asthma occurred in 2% of subjects receiving NUCALA, 5% of subjects in the ‘mepolizumab all doses combined’ group, and 9% of subjects receiving placebo.

Serious adverse events were reported in 17% and 23% of children receiving NUCALA in the short- and long-term phases of study 200363, respectively. Serious adverse events of asthma occurred in 8% and 17% of subjects, respectively.

Adverse Events leading to withdrawal from clinical trial

In placebo-controlled studies that enrolled adults and adolescents, 2% of subjects receiving NUCALA and 3% of subjects in the ‘mepolizumab all doses combined’ group withdrew due to an adverse event compared with 3% of subjects receiving placebo. The most frequent AE leading to withdrawal was asthma, which was reported by <1% of subjects in both the ‘mepolizumab all doses combined’ and placebo groups; no subjects receiving NUCALA withdrew due to asthma. Adverse events leading to withdrawal in subjects receiving NUCALA included atrial flutter (1 subject), injection site reaction (1 subject) and urticaria (1 subject). An additional subject was withdrawn after receiving one dose of NUCALA due to a pre-existing medical condition of left bundle branch block. Adverse events leading to withdrawal in the ‘mepolizumab all doses combined’ group occurring in more than one subject included...
hypersensitivity (3 subjects: 1 received 250 mg IV and 2 received 750 mg IV) and arthralgia (2 subjects: 1 received 75 mg IV and 1 received 250 mg IV).

One child receiving NUCALA withdrew from study 200363 due to worsening asthma.

**Immunogenicity**

The detection of anti-drug antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease.

In placebo-controlled clinical studies that enrolled adults and adolescents, 15/260 (6%) subjects treated with NUCALA 100 mg SC every 4 weeks had detectable anti-mepolizumab antibodies after having received at least one dose of NUCALA and neutralizing antibodies were detected in one adult subject receiving NUCALA. In children from study 200363, 2/35 (6%) subjects had detectable anti-mepolizumab antibodies after having received at least one dose of NUCALA during the short-term (12-week) phase of the study; no children had detectable neutralizing antibodies. No children had detectable anti-mepolizumab antibodies during the long-term (52-week) phase of the study.

Overall, the clinical impact of the presence of anti-mepolizumab antibodies is not known.

The immunogenicity profile of NUCALA in a select subset of adult and adolescent subjects with severe eosinophilic asthma (n=998) who were tolerant to NUCALA and entered the open-label, uncontrolled, extension studies was consistent to that observed in the placebo-controlled studies; 60/992 (6%) subjects treated with NUCALA had detectable anti-mepolizumab antibodies. All subjects were negative for neutralizing antibodies.

**Adverse Events of Special Interest**

**Systemic Allergic Reactions:** In adults and adolescents, systemic hypersensitivity reactions were reported by 1% of subjects receiving NUCALA, 1% of subjects in the ‘mepolizumab all doses combined’ group and 2% of subjects receiving placebo. All hypersensitivity reactions were reported as mild or moderate severity.

Systemic hypersensitivity events were reported in 3% and 7% of children in the short- and long-term phases of study 200363, respectively. In the short-term phase, one child reported pruritus that was mild in intensity. In the long-term phase, one child reported rash and pruritus that were moderate in intensity, and one child reported a serious event of anaphylactic shock (anaphylactic shock due to peanut allergy) that was severe in intensity; anaphylactic shock was considered unrelated to NUCALA. All events resolved without NUCALA interruption.

**Infections:** In adults and adolescents, overall infections were reported with similar frequency in the NUCALA (52%), ‘mepolizumab all doses combined’ (57%), and placebo (58%) treatment groups. Serious infections were reported by 3% of subjects in the NUCALA, ‘mepolizumab all
doses combined’, and placebo treatment groups. Serious infectious adverse events that were reported in more than one subject in the ‘mepolizumab all doses combined’ group included pneumonia (4 subjects: 1 received NUCALA, 1 received 75 mg IV, 2 received 750 mg IV compared to 3 who received placebo); lobar pneumonia (2 subjects received 75 mg compared to 1 who received placebo), and herpes zoster (2 subjects received NUCALA compared to 0 in the placebo group). Opportunistic infections were infrequent and were reported in <1% of subjects in the placebo group and in 1% of subjects receiving NUCALA. One subject receiving NUCALA reported a helminth infection of parasitic gastroenteritis, which resolved with treatment; NUCALA was continued.

Infection adverse events were reported in 50% and 73% of children treated with NUCALA in the short- and long-term phases of study 200363, respectively. Of these infections, 8% and 3% were serious, respectively.

**Cardiovascular Events:** In adults and adolescents, cardiac events were reported in 3% of placebo and ‘mepolizumab all doses combined’ patients, and 2% of patients that received mepolizumab 100 mg SC/75 mg IV. Serious cardiac events were reported in <1% of subjects in the NUCALA, ‘mepolizumab all doses combined’, and placebo treatment groups.

Vascular events were reported with similar frequency in the NUCALA (3%), ‘mepolizumab all doses combined’ (5%), and placebo (6%) treatment groups. Serious vascular events were reported in <1% in the ‘mepolizumab all doses combined’ group and 0% in both the NUCALA and placebo treatment groups.

No on-treatment cardiovascular events were reported in children enrolled in study 200363.

**Injection Site Reactions:** In adults and adolescents, injection site reactions were reported more frequently in the NUCALA group (8%) compared with the ‘mepolizumab all doses combined’, and placebo treatment groups (3% in both). Symptoms included mild or moderate rash, itching, swelling, burning, and pain at the injection site.

Injection site reactions were reported in 14% and 0% of children treated with NUCALA in the short- and long-term phases of study 200363, respectively. Symptoms were mild and included erythema, swelling, rash, itching, pain, and injection site wheal.

**Neoplasms and Malignancies:** In adults and adolescents, neoplasms were reported in 2% of subjects in the placebo group and <1% of subjects in both the NUCALA and the ‘mepolizumab all doses combined’ groups. Malignancies were reported in 3 subjects (<1%) in the placebo group and 2 subjects (<1%) in the ‘mepolizumab all doses combined’ group; no malignancies were reported in subjects receiving NUCALA. Malignancies reported during the studies included basal cell carcinoma, basosquamous carcinoma, prostate cancer, uterine cancer, and squamous cell carcinoma.

No neoplasms or malignancies were reported in children enrolled in study 200363.
Less Common Clinical Trial Adverse Events

In addition to the adverse events shown in Table 1, adverse events reported less commonly (defined as <1% in the ‘mepolizumab all doses combined’ treatment group) from the placebo-controlled severe asthma clinical trials in adults and adolescents and were reported in 2 or more patients receiving NUCALA compared to no reports in patients receiving placebo are summarized below.

**Blood and lymphatic system disorders**: iron deficiency anemia

**Endocrine disorders**: cushingoid

**Eye disorders**: lacrimation increased

**Gastrointestinal disorder**: dry mouth, gastrointestinal disorder

**Injury, poisoning and procedural complications**: administration related reaction, wrist fracture, stress fracture

**Metabolism and nutrition disorders**: diabetes mellitus, hypoglycemia, vitamin B12 deficiency

**Musculoskeletal and connective tissue disorders**: musculoskeletal stiffness

**Renal and urinary disorders**: pollakiuria

**Skin and subcutaneous disorder**: miliaria

**Eosinophilic Granulomatosis with Polyangiitis**

The safety of NUCALA has been studied in a double-blind, randomized, placebo-controlled, multicentre, 52-week treatment trial. A total of 136 subjects with EGPA were evaluated. Subjects received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Adverse events from this study that were reported by 5% or more of patients treated with NUCALA 300 mg SC and that were reported more frequently than placebo (≥1% difference from placebo) are presented in Table 3.
Table 3  On-treatment Adverse Events with ≥5% incidence with NUCALA and ≥1% more common with NUCALA than placebo in subjects with EGPA

<table>
<thead>
<tr>
<th>Adverse Events¹</th>
<th>NUCALA 300 mg SC (N =68) n (%)</th>
<th>Placebo (N = 68) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ear and labyrinth disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vertigo</td>
<td>5 (7%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision blurred</td>
<td>4 (6%)</td>
<td>2 (3%)</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>12 (18%)</td>
<td>8 (12%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>11 (16%)</td>
<td>4 (6%)</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site reaction²</td>
<td>9 (13%)</td>
<td>7 (10%)</td>
</tr>
<tr>
<td>Asthenia</td>
<td>5 (7%)</td>
<td>3 (4%)</td>
</tr>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinusitis</td>
<td>14 (21%)</td>
<td>11 (16%)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>14 (21%)</td>
<td>11 (16%)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>5 (7%)</td>
<td>4 (6%)</td>
</tr>
<tr>
<td>Acute sinusitis</td>
<td>6 (9%)</td>
<td>2 (3%)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>5 (7%)</td>
<td>3 (4%)</td>
</tr>
<tr>
<td>Fungal skin infection</td>
<td>4 (6%)</td>
<td>3 (4%)</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>5 (7%)</td>
<td>2 (3%)</td>
</tr>
<tr>
<td>Oral herpes</td>
<td>4 (6%)</td>
<td>3 (4%)</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>5 (7%)</td>
<td>0</td>
</tr>
<tr>
<td>Weight increased</td>
<td>4 (6%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td><strong>Injury, poisoning and procedural complications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ligament sprain</td>
<td>4 (6%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>15 (22%)</td>
<td>12 (18%)</td>
</tr>
<tr>
<td>Back pain</td>
<td>9 (13%)</td>
<td>6 (9%)</td>
</tr>
<tr>
<td>Neck pain</td>
<td>8 (12%)</td>
<td>2 (3%)</td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
<td>6 (9%)</td>
<td>2 (3%)</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>22 (32%)</td>
<td>12 (18%)</td>
</tr>
<tr>
<td>Paraesthesia</td>
<td>4 (6%)</td>
<td>3 (4%)</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oropharyngeal pain</td>
<td>8 (12%)</td>
<td>5 (7%)</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>9 (13%)</td>
<td>6 (9%)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>6 (9%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>Urticaria</td>
<td>4 (6%)</td>
<td>1 (1%)</td>
</tr>
</tbody>
</table>
The most common symptoms associated with subcutaneous injections included: erythema, bruising, pain, swelling, and warm to touch.

No additional adverse drug reactions (events considered to be possibly related to treatment with mepolizumab) were identified to those reported in the severe asthma trials.

Fatalities

In clinical studies that included patients with EGPA, 2 subjects receiving NUCALA died (fatal cardiac arrest in both cases). One death occurred in an open-label long-term access program containing subjects that participated in the placebo-controlled trial. Neither death was considered related to study medication by the investigators.

Serious Adverse Events

Serious adverse events were reported in 18% of subjects receiving NUCALA and 26% of subjects receiving placebo.

Adverse Events leading to withdrawal from clinical trial

Two subjects (3%) receiving NUCALA and 1 (1%) subject receiving placebo withdrew due to an adverse event. Adverse events leading to withdrawal in subjects receiving NUCALA included cardiac arrest (1 subject) and hypersensitivity (1 subject). Adverse events leading to withdrawal in subjects receiving placebo included pneumonia (1 subject).

Immunogenicity

In subjects treated with NUCALA 1/68 (1%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any subjects with EGPA.

Adverse Events of Special Interest

Systemic Allergic Reactions: Systemic hypersensitivity reactions were reported in 4% of subjects that received NUCALA and in 1% of subjects that received placebo. One subject receiving NUCALA reported a hypersensitivity reaction that was serious and severe, but was not considered anaphylaxis. Symptoms associated with this reaction included malaise, hypertension, chills, pallor, cold extremities, warm sensation in trunk and neck, dyspnea, and stridor. Two of the four reported events of hypersensitivity occurred on the day of dosing.

Infections: Overall infections were reported with similar frequency in the NUCALA (84%) and placebo (78%) treatment groups. Serious infections were reported in 6% of subjects in the NUCALA treatment group and 15% of subjects in the placebo treatment group. Events considered to represent potential opportunistic infections were reported in 7% of subjects receiving NUCALA and in 3% of subjects in the placebo group.

Cardiovascular Events: Cardiac events were reported in 6% of subjects that received NUCALA and 9% subjects that received placebo. Serious cardiac events were reported in 1% of subjects in
the NUCALA treatment group and 3% of subjects in the placebo treatment group.

**Injection Site Reaction:** Injection site reactions were reported at a rate of 15% in subjects treated with NUCALA compared with 13% in subjects treated with placebo. Common symptoms included erythema, bruising, pain, swelling, and warm to touch.

**Neoplasms and Malignancies:** Neoplasms were reported in 1% of subjects in the NUCALA group and 4% of subjects in the placebo group. Malignancies were reported in no subjects receiving NUCALA and 2 subjects (3%) in the placebo group.

**Less Common Clinical Trial Adverse Events**

In addition to the events shown in Table 3, adverse events reported less commonly (defined as <5% in the ‘mepolizumab’ treatment group) from the placebo-controlled MEA115921 clinical trial and were reported in 2 or more patients receiving NUCALA compared to no reports in patients receiving placebo are summarized below.

**Blood and lymphatic disorders:** anemia

**Ear and labyrinth disorders:** deafness, tinnitus

**Endocrine disorders:** adrenal insufficiency, steroid withdrawal syndrome

**Eye disorders:** eye pruritic, eye pain

**Gastrointestinal disorder:** hemorrhoids

**Immune system disorders:** food allergy

**Infections and infestations:** candida infection, herpes simplex, pharyngitis, influenza like illness

**Injury, poisoning and procedural complications:** muscle strain, skin abrasion

**Investigations:** aspartate aminotransferase increased, gamma-glutamyltransferase increased

**Musculoskeletal and connective tissue disorders:** bursitis

**Respiratory, thoracic and mediastinal disorders:** nasal polyps, pulmonary pain, rhinitis allergic

**Skin and subcutaneous disorder:** skin lesion, rash pruritic

**Vascular disorders:** hot flush
Post-Market Adverse Drug Reactions

The following adverse reactions have been identified during post-approval use of NUCALA:

**Immune System Disorders:** Hypersensitivity reactions including anaphylaxis

**DRUG INTERACTIONS**

No formal interaction studies have been performed with NUCALA.

**Drug-Drug Interactions**

Interactions with other drugs have not been formally studied.

**Drug-Food Interactions**

Interactions with food have not been studied, as NUCALA is administered subcutaneously.

**Drug-Herb Interactions**

Interactions with herbal products have not been studied.

**Drug-Laboratory Interactions**

Interactions with laboratory tests have not been studied.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

**General:**
NUCALA should only be administered as a subcutaneous injection.

NUCALA is intended for use under the guidance of a physician who is experienced in the monitoring of signs and symptoms of hypersensitivity after administration of biologic agents.

**Lyophilized powder**
NUCALA (mepolizumab for injection) should be reconstituted and administered by a qualified healthcare professional who is prepared to manage anaphylaxis that can be life-threatening (see WARNINGS AND PRECAUTIONS). Following reconstitution, NUCALA should be used immediately upon withdrawal from the vial into a syringe (see DOSAGE AND ADMINISTRATION, Administration).

This is the only dosage form acceptable to deliver a 40 mg dose.
Solution in pre-filled autoinjector or safety syringe
NUCALA (mepolizumab injection) may be self-administered by the patient or administered by a
caregiver if their healthcare professional determines that it is appropriate and the patient or
caregiver are trained in injection techniques (see DOSAGE AND ADMINISTRATION,
Administration).

The pre-filled autoinjector and safety syringe deliver a 100 mg dose of mepolizumab, and are not
suitable for those who require a 40 mg dose of mepolizumab (i.e. children 6 to 11 years of age
with severe eosinophilic asthma).

**Recommended Dose and Dosage Adjustment**

**Severe Eosinophilic Asthma:**

**Adults and Adolescents (≥ 12 years of age):**
The recommended dose of NUCALA is 100 mg administered subcutaneously once every 4
weeks.

**Children (6-11 years of age)**
The recommended dose of NUCALA is 40 mg administered subcutaneously once every 4 weeks.

*Only the lyophilized powder formulation can provide the recommended 40 mg dose and
should be used for dosing children 6 to 11 years of age.*

Each vial of lyophilized powder should be used for a single patient, and any remainder in the vial
should be discarded.

**Eosinophilic Granulomatosis with Polyangiitis:** The recommended dose of NUCALA is 300
mg administered subcutaneously once every 4 weeks.

The 300 mg dose for treatment of Eosinophilic Granulomatosis with Polyangiitis requires the
administration of 3 separate 100 mg injections (see DOSAGE AND ADMINISTRATION,
Administration).

**Pediatrics (< 18 years of age)**

**Severe Eosinophilic Asthma:** NUCALA is not indicated in patients under 6 years of age.

Dosing in children was derived using modelling and simulation of adult and pediatric PK data
(see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Patient
Populations).

**Eosinophilic Granulomatosis with Polyangiitis:** NUCALA is not indicated in patients under 18
years of age.
Geriatrics (≥ 65 years of age)

No dosage adjustment is required for elderly patients (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Patient Populations).

Renal Impairment

Dosage adjustments in patients with renal impairment are unlikely to be required (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Patient Populations).

Hepatic Impairment

Dosage adjustments in patients with hepatic impairment are unlikely to be required (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Patient Populations).

Administration

Lyophilized powder

Instructions for reconstitution: NUCALA does not contain a preservative, therefore, reconstitution should be carried out by a healthcare professional under aseptic conditions.

1. Reconstitute the NUCALA powder in the vial with 1.2 mL of sterile Water for Injection, preferably using a 2 to 3 mL syringe and a 21 gauge to 27 gauge needle. The reconstituted solution will contain a concentration of 100 mg/mL mepolizumab and may appear colourless to pale yellow or pale brown. Do not mix with other medications.

2. The stream of sterile Water for Injection should be directed vertically onto the centre of the lyophilized cake. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 10 seconds with circular motion at 15-second intervals until the powder is dissolved. Reconstitution is typically complete within 5 minutes after the sterile water has been added, but it may take additional time.

   Note: Do not shake the reconstituted solution during the procedure as this may lead to excessive foaming or precipitation.

3. If a mechanical reconstitution device (swirler) is used to reconstitute NUCALA, reconstitution can be accomplished by swirling at 450 rpm for no longer than 10 minutes. Alternatively, swirling at 1000 rpm for no longer than 5 minutes is acceptable.

4. Visually inspect the reconstituted NUCALA for particulate matter and clarity prior to use. The solution should be clear to opalescent, and colourless to pale yellow or pale brown, free of visible particles. Small air bubbles or mild foaming are expected, however, and are
acceptable. If particulate matter remains in the solution, or if the solution appears cloudy or milky, the solution must not be used.

5. If more than one vial is required for administration of the prescribed dosage, repeat steps 1 to 4.

6. If the reconstituted solution of NUCALA in the vial is not used immediately:
   - Store below 30ºC.
   - Do not freeze.
   - Discard if not used within 8 hours of reconstitution.

**Instructions for administration of each 100 mg dose:** For subcutaneous administration, a 1 mL polypropylene syringe fitted with a disposable needle 21 gauge to 27 gauge x 0.5 inch (13 mm) should preferably be used.

1. Just prior to administration, remove 1 mL of reconstituted NUCALA. Do not shake the reconstituted NUCALA solution during the procedure as this could lead to product foaming or precipitation.

2. Administer the 1 mL injection (equivalent to 100 mg mepolizumab) subcutaneously into the upper arm, thigh, or abdomen.

If more than one vial is required for administration of the prescribed dosage, repeat steps 1 to 2. It is recommended that individual injection sites be separated by at least 5 cm.

**Instructions for administration of each 40 mg dose:** For subcutaneous administration, a 1 mL polypropylene syringe fitted with a disposable needle 21 gauge to 27 gauge x 0.5 inch (13 mm) should preferably be used.

1. Just prior to administration, remove 0.4 mL of reconstituted NUCALA. Do not shake the reconstituted NUCALA solution during the procedure as this could lead to product foaming or precipitation. Dispose of the remaining solution.

2. Administer the 0.4 mL injection (equivalent to 40 mg mepolizumab) subcutaneously into the upper arm, or thigh.

**Missed Dose**

If a dose is missed or the patient is unable to attend an appointment for one of the injections, the missed dose should be administered as soon as possible.

**Solution in pre-filled autoinjector or safety syringe**

A patient may self-inject or the caregiver may administer NUCALA injection subcutaneously after the healthcare professional determines it is appropriate. The healthcare professional should
provide the patient or caregiver with proper training in injection technique and on the instructions for administration prior to use.

The pre-filled autoinjector and safety syringe deliver a 100 mg dose of mepolizumab, and are not suitable for those who require a 40 mg dose of mepolizumab.

Ensure the PATIENT MEDICATION INFORMATION and INSTRUCTIONS FOR USE are followed.

Instructions for administration:

1. Remove the prefilled autoinjector or prefilled syringe from the refrigerator and allow it to sit at room temperature for 30 minutes prior to injection. Do not warm NUCALA in any other way.

2. Prior to administration, visually inspect the window of the prefilled autoinjector or the prefilled syringe for particulate matter or discoloration. NUCALA injection should be clear to opalescent, colourless to pale yellow or pale brown in color. Do not use NUCALA injection if the product exhibits discoloration, cloudiness, or particulate matter. Do not use the NUCALA prefilled autoinjector or prefilled syringe if dropped on a hard surface.

3. Administer the subcutaneous injection into the thigh or abdomen, avoiding the 5 cm (2 inches) around the navel. The upper arm can also be used if a caregiver administers the subcutaneous injection.

4. For use in EGPA, make sure the injection sites for each subcutaneous injection are separated by at least 5 cm (2 inches).

5. Never give injections into areas where the skin is tender, bruised, red, or hard.

Missed Dose

If a dose is missed, instruct the patient or patient caregiver to administer a dose as soon as possible. Thereafter, the patient can resume dosing on the usual day of administration. If the next dose is already due, then administer as planned.
OVERDOSAGE

There is no clinical experience with overdose of NUCALA.

Single doses of up to 1500 mg were administered intravenously in a clinical trial to patients with eosinophilic disease without evidence of dose-related toxicities.

Treatment

There is no specific treatment for an overdose with NUCALA. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

NUCALA is a targeted anti-interleukin-5 (IL-5) IgG1 kappa monoclonal antibody. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to soluble IL-5 with high affinity (a dissociation constant of 100 pM), preventing IL-5 from binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface, thereby reducing the production and survival of eosinophils. Inflammation is an important component in the pathogenesis of asthma and eosinophilic granulomatosis with polyangiitis. The reduction of eosinophilic inflammation may play an important role in eliciting a therapeutic effect in the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis; however, the precise mechanism of mepolizumab action has not been definitively established.

Pharmacodynamics

Severe Eosinophilic Asthma: Following treatment with mepolizumab, dose-dependent pharmacodynamic responses, i.e. reductions in blood eosinophil levels from baseline, were observed in adult asthma patients with mean baseline blood eosinophil levels greater than 300 cells/µL (ranged 150 – 2420 cells/µL). Subjects were assigned to receive one of four mepolizumab treatments (administered every 4 weeks for a total of three doses): 12.5 mg SC, 125 mg SC, 250 mg SC, or 75 mg IV. Sixty-six (66) of the 70 randomized subjects completed the trial. A reduction in blood eosinophil levels was observed in all treatment groups by Day 3. On Day 84 (4 weeks post-last dose), model-estimated inhibition of blood eosinophils was 57% (95% CI: 42, 69), 86% (95% CI: 83, 88), 86% (95% CI: 83, 89), and 88% (95% CI: 85, 90) in the 12.5 mg SC, 75 mg IV, 125 mg SC, and 250 mg SC treatment groups, respectively. The SC model-estimated doses to provide 50% and 90% of maximal inhibition of blood eosinophils at Day 84 were 11 and 99 mg, respectively.
In adults and adolescents, following SC administration of mepolizumab 100 mg every 4 weeks for 32 weeks, blood eosinophils were reduced to a geometric mean count of 40 cells/µL, which corresponds to a geometric mean reduction of 84% compared with placebo. Consistent results were observed following mepolizumab IV administration at 75 mg and SC administration at 100 mg (Figure 1). The magnitude of blood eosinophil reduction in a select subset of adult and adolescent subjects with severe eosinophilic asthma (n=998) who were tolerant to NUCALA and entered the open-label, uncontrolled, extension studies and were treated with NUCALA 100 mg SC for a median of 2.8 years (range 4 weeks to 4.5 years) was consistent with that observed in the placebo-controlled studies.

In children (n = 29), following either mepolizumab 40 mg (for a weight < 40 kg) or 100 mg (for a weight ≥ 40 kg) administered subcutaneously every 4 weeks for 52 weeks, blood eosinophils were reduced to a geometric mean count of 48 cells/µL (85% reduction from baseline) and 44 cells/µL (87% reduction from baseline), respectively.

In adults, adolescents, and children, the magnitude of reduction was observed at the first post-dose measurement interval (4 weeks) and was maintained throughout the treatment period.

**Figure 1** Reduction in blood eosinophils from baseline over 32 weeks (MENSA in adults and adolescents)

![Graph showing reduction in blood eosinophils over time](image)

**Eosinophilic Granulomatosis with Polyangiitis:** Following SC administration of mepolizumab 300 mg every 4 weeks for 52 weeks in subjects with EGPA, blood eosinophils were reduced to a geometric mean count of 38 cells/µL. There was a geometric mean reduction of 83% compared
to placebo and this magnitude of reduction was observed within 4 weeks of treatment (see CLINICAL TRIALS).

**Pharmacokinetics**
Following SC dosing in subjects with moderate/severe asthma, mepolizumab exhibited approximately dose-proportional pharmacokinetics over a dose range of 12.5 mg to 250 mg.

In a population pharmacokinetic analysis, the pharmacokinetics of mepolizumab in subjects with EGPA dosed at 300 mg SC is consistent with that reported in subjects with asthma. Systemic exposure following administration of mepolizumab 300 mg SC in subjects with EGPA was approximately 3 times that of mepolizumab 100 mg administered SC in subjects with severe asthma.

Following a single 100 mg SC administration in healthy subjects, mepolizumab systemic exposure was comparable between formulations.

**Absorption:** Following SC administration to healthy subjects or patients with asthma, mepolizumab was absorbed slowly with a median time to reach maximum plasma concentration (T_{max}) ranging from 4 to 8 days.

Following a single 250 mg subcutaneous administration in the abdomen, thigh or arm of healthy subjects, mepolizumab absolute bioavailability was 64%, 71% and 75%, respectively. In patients with asthma, the absolute bioavailability of mepolizumab administered SC in the arm ranged from 74%-80%.

Following repeat SC administration every 4 weeks, steady-state is reached by 16 weeks and there is approximately a two-fold accumulation at steady state.

**Distribution:** Following a single IV administration of mepolizumab to patients with asthma, the mean volume of distribution is 55 to 85 mL/kg.

**Metabolism:** Mepolizumab is a humanized IgG1 monoclonal antibody degraded by proteolytic enzymes which are widely distributed in the body and not restricted to hepatic tissue.

**Elimination:** Following SC administration of mepolizumab, the mean terminal half-life (t_{1/2}) ranged from 16 to 22 days. In a population pharmacokinetic analysis, the estimated mepolizumab systemic clearance was 3.1 mL/day/kg.

**Special Patient Populations**

**Race or Gender**
A population pharmacokinetics analysis of mepolizumab data indicated that there was no significant effect of race and gender on mepolizumab clearance.

**Children (6 to 11 years of age)**
Mepolizumab pharmacokinetics following SC administration in subjects 6 to 11 years of age with severe eosinophilic asthma (n = 36) was investigated in the 12-week treatment phase of the
uncontrolled, open-label study (200363). Exposures (as measured by AUC) following SC administration of either 40 mg (for a weight < 40 kg) or 100 mg (for a weight ≥ 40 kg) were 1.32 and 1.97 times of that observed in adults and adolescents administered 100 mg. Based on a population pharmacokinetic model updated by these results, simulation of a 40 mg SC dose every 4 weeks in children, irrespective of weight, resulted in predicted exposures similar to those observed in adults and adolescents.

*Geriatrics (≥ 65 years of age)*
No formal studies have been conducted in elderly patients. However, in the population pharmacokinetic analysis, there were no indications of an effect of age (range included 12-82 years) on the pharmacokinetics of mepolizumab.

*Renal Impairment*
No formal studies have been conducted to investigate the effect of renal impairment on the pharmacokinetics of mepolizumab. Based on population pharmacokinetic analyses, mepolizumab clearance was comparable between patients with creatinine clearance values between 50-80 mL/min and patients with normal renal function. There are limited data available in patients with creatinine clearance values <50 mL/min; however, mepolizumab is not cleared renally.

*Hepatic Impairment*
No formal studies have been conducted to investigate the effect of hepatic impairment on the pharmacokinetics of mepolizumab. Since mepolizumab is degraded by widely distributed proteolytic enzymes, not restricted to hepatic tissue, changes in hepatic function are unlikely to have any effect on the elimination of mepolizumab.

**STORAGE AND STABILITY**

**Lyophilized powder**

**Unopened vial**
Store in the original carton below 25º C until use. Do not freeze. Protect from light.

**Reconstituted solution**
After reconstitution with Water for Injection, the product is stable for up to 8 hours when stored below 30ºC. Do not freeze. During administration, protection from light is not necessary. Any unused concentrate or solution remaining after 8 hours must be discarded.

**Solution in pre-filled autoinjector or safety syringe**
Store in the original carton to protect from light. The pre-filled autoinjector or safety syringe should be stored refrigerated (2ºC to 8ºC), but if necessary can be removed from the refrigerator and kept in the unopened carton for up to 7 days at below 30ºC, when protected from light. Do not freeze. Discard if unopened carton is left out of the refrigerator for more than 7 days.
The pre-filled autoinjector or safety syringe must be administered within 8 hours once the carton is opened. Discard if not administered within 8 hours.

**SPECIAL HANDLING INSTRUCTIONS**

Do not mix the reconstituted NUCALA solution for injection with other medicinal products.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

NUCALA is available in the following formats:

**Lyophilized powder**
NUCALA is available as a sterile preservative-free, lyophilized powder for subcutaneous injection. NUCALA is presented in a single-use 10 mL type I glass vial with bromobutyl rubber (latex-free) stopper and a grey aluminum overseal with a plastic flip-cap.

Each single-use vial contains 144 mg of lyophilized mepolizumab. Upon reconstitution with 1.2 mL of sterile Water for Injection, USP, each vial delivers 100 mg mepolizumab in 1 mL, with heptahydrate, polysorbate 80, sodium phosphate dibasic, and sucrose, at a pH of 7.0.

This is the only dosage form acceptable to deliver a 40 mg dose.

**Solution in pre-filled autoinjector or safety syringe**
NUCALA is available as a sterile, clear to opalescent, colourless to pale yellow or pale brown, preservative-free solution for subcutaneous use. It is supplied in the following formats:

- A single-dose, 1-mL, pre-filled autoinjector with a fixed 29-gauge, half-inch needle;
- A single-dose, 1-mL, pre-filled safety syringe with a fixed 29-gauge, half-inch needle with a needle guard.

Each 1 mL pre-filled autoinjector or safety syringe delivers 100 mg mepolizumab, with citric acid monohydrate, EDTA disodium dihydrate, polysorbate 80, sodium phosphate dibasic heptahydrate, and sucrose, at a pH of 6.3.

As the pre-filled autoinjector and safety syringe deliver a 100 mg dose of mepolizumab, they are not suitable for those who require a 40 mg dose of mepolizumab.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

<table>
<thead>
<tr>
<th>Proper name:</th>
<th>Mepolizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical name:</td>
<td>Not applicable. Mepolizumab is not a chemical. It is an immunoglobulin (recombinant human IgG1 monoclonal antibody).</td>
</tr>
</tbody>
</table>

Molecular formula and molecular mass: \( \text{C}_{6476}\text{H}_{10084}\text{N}_{1732}\text{O}_{2028}\text{S}_{46} \) (without oligosaccharide)

The polypeptide molecular mass is 146 kDa and the carbohydrate molecular mass is approximately 3 kDa resulting in a total estimated molecular mass of 149 kDa for mepolizumab.

Structural formula: Mepolizumab is a humanized IgG1 kappa immunoglobulin and consists of two heavy chains of 449 amino acids and two light chains of 220 amino acids. The heavy and light chains are covalently linked by a single disulfide bond and the heavy chains are linked to each other by two disulfide bonds resulting in a typical IgG molecule.

Physicochemical properties: Mepolizumab is a clear to opalescent, colourless to pale yellow or pale brown solution.

Product Characteristics

Mepolizumab is a humanized monoclonal antibody (IgG1, kappa) produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells. Mepolizumab is expressed as a soluble glycoprotein secreted into an animal component free cell culture medium, purified and formulated to produce bulk drug substance (BDS).
**CLINICAL TRIALS**

**Severe Eosinophilic Asthma**

The efficacy and safety of adjunctive mepolizumab treatment in severe eosinophilic asthma was evaluated in 2 phase III, randomized, double-blind, parallel-group clinical trials of 24 to 32 weeks’ duration in 711 subjects aged 12 years and older, including 27 adolescents (Table 4).

- Exacerbation trial (MENSA) – 75 mg IV or 100 mg SC vs. placebo
- Oral corticosteroid (OCS) reduction trial (SIRIUS) – 100 mg SC vs. placebo

These clinical trials were designed to evaluate the efficacy and safety of mepolizumab administered once every 4 weeks in subjects with severe eosinophilic asthma not adequately controlled on high-dose inhaled corticosteroid (ICS) (an equivalent of ≥1000 μg fluticasone propionate/day for subjects 18 years of age and older) or medium-dose ICS (an equivalent of ≥500 μg fluticasone propionate/day for subjects 12 to 17 years of age) and an additional controller(s) (e.g., long-acting beta-agonist (LABA), leukotriene receptor antagonist (LTRA), and/or theophylline) with or without oral corticosteroids (OCS)). In SIRIUS, all subjects were required to be on regular maintenance treatment with OCS.

An open-label, uncontrolled clinical trial evaluated the pharmacokinetics and pharmacodynamics (12 week duration) and safety (52 week duration) of mepolizumab treatment in 36 children (6 to 11 years of age) with severe eosinophilic asthma.

**Table 4**  
**Summary of Trial Designs in Severe Eosinophilic Asthma**

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
</tr>
</thead>
</table>
| MEA115588     | 32-week, multicentre, randomised, double-blind, placebo-controlled, double-dummy, parallel-group study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma | NUCALA 100 mg SC Mepolizumab 75 mg IV\textsuperscript{1} Placebo Duration: 32 weeks | n=194\(\text{female}\)  
\(\text{m}=191\)\(\text{male}\) Total: 576 | 50 years (12-82) | Female: 329 (57%)  
Male: 247 (43%) |
### Study #

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEA115575 (SIRIUS)</td>
<td>24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group study of mepolizumab adjunctive therapy to reduce oral corticosteroid use in subjects with severe eosinophilic asthma</td>
<td>NUCALA 100 mg SC Placebo Duration: 24 weeks</td>
<td>n=69 n=66</td>
<td>50 years (16-74)</td>
<td>Female: 74 (55%) Male: 61 (45%)</td>
</tr>
<tr>
<td>200363</td>
<td>An open-label, uncontrolled, study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered SC in children from 6 to 11 years of age with severe eosinophilic asthma</td>
<td>NUCALA 40 mg SC (for a weight &lt; 40 kg) or NUCALA 100 mg SC (for a weight ≥ 40 kg) Duration: 12 weeks (short-term phase) 52 weeks (long-term phase)</td>
<td>n=36 n=30</td>
<td>8.6 years (5-12) 8.6 years (6-12)</td>
<td>Female: 11 (31%) Male: 25 (69%) Female: 10 (33%) Male: 20 (67%)</td>
</tr>
</tbody>
</table>

IV = intravenous; SC = subcutaneous

¹NUCALA is not indicated for intravenous use and should only be administered by the SC route.

**Mepolizumab as adjunctive therapy in patients with Severe Asthma (MENSA)**

**Study Design**

MENSA was a 32-week, randomized, double-blind, parallel-group study evaluating the efficacy and safety of mepolizumab 75 mg IV or NUCALA 100 mg SC vs. placebo administered every four weeks in the add-on treatment of severe eosinophilic asthma in 576 subjects (Table 4). MENSA was the only pivotal exacerbation study to evaluate the direct effect of SC dosing on the exacerbation rate. The 100 mg SC and 75 mg IV doses were chosen to provide consistent systemic mepolizumab exposure and reduction of blood eosinophils over the treatment period (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics and Pharmacokinetics, Absorption).

Subjects had a history of two or more asthma exacerbations in the past 12 months despite regular use of high-dose ICS (or medium-dose ICS for adolescents) plus an additional controller(s) (e.g., LABA, LTRA, and/or theophylline) with or without OCS. Additionally, subjects had blood eosinophils of ≥150 cells/μL (≥0.15 GI/L) at initiation (within 6 weeks of first dose) or blood eosinophils of ≥300 cells/μL (≥0.3 GI/L) within 12 months of enrollment.
The primary endpoint was the frequency of clinically significant exacerbations of asthma, defined as worsening of asthma requiring use of oral/systemic corticosteroids and/or hospitalization and/or emergency room visits. For subjects on maintenance OCS, an exacerbation requiring OCS was defined as the use of oral/systemic corticosteroids at least double the existing maintenance dose for at least 3 days.

During the study, the percentage of patients who discontinued treatment and withdrew prematurely from the NUCALA 100 mg SC group, mepolizumab 75 mg IV group, and placebo group was 5%, 8% and 6%, respectively. The most common reason for discontinuation of treatment was patients withdrawing consent (3% overall).

**Patient Demographics and Baseline Characteristics**
Demographics and baseline characteristics were balanced between treatment groups (Table 5). During the trial, subjects continued their baseline asthma therapy, including high-dose ICS (or medium-dose ICS for adolescents), with an additional controller(s). Additionally, 24% of the subjects were on maintenance OCS (median 10.0 mg/day).
Table 5  Summary of patient demographics and baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>NUCALA 100 mg SC N=194</th>
<th>Mepolizumab 75 mg IV N=191</th>
<th>Placebo N=191</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age in years (range)</td>
<td>51 (12 - 81)</td>
<td>50 (13 - 82)</td>
<td>49 (12 - 76)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>78 (40)</td>
<td>85 (45)</td>
<td>84 (44)</td>
</tr>
<tr>
<td>Female</td>
<td>116 (60)</td>
<td>106 (55)</td>
<td>107 (56)</td>
</tr>
<tr>
<td>Mean duration of asthma in years (SD)</td>
<td>20.5 (12.9)</td>
<td>19.8 (14.0)</td>
<td>19.5 (14.6)</td>
</tr>
<tr>
<td>Mean % Predicted pre-bronchodilator FEV₁ (SD)</td>
<td>59.3 (17.6)</td>
<td>61.4 (18.3)</td>
<td>62.4 (18.1)</td>
</tr>
<tr>
<td>Geometric mean baseline blood eosinophil count (SD on log scale) - G/L</td>
<td>0.29 (1.050)</td>
<td>0.28 (0.987)</td>
<td>0.32 (0.938)</td>
</tr>
<tr>
<td>Mean number of exacerbations in the previous year (SD)</td>
<td>3.8 (2.7)</td>
<td>3.5 (2.2)</td>
<td>3.6 (2.8)</td>
</tr>
</tbody>
</table>

Study Results
The reduction in the rate of clinically significant exacerbations of asthma was statistically significant (p<0.001) for both mepolizumab treatment groups compared with placebo (Table 6).

Compared with placebo, the reduction in the rate of exacerbations that required hospitalization or emergency room visits was statistically significant for NUCALA 100 mg SC, but not for mepolizumab 75 mg IV (Table 6). Additionally, the rate of clinically significant exacerbations requiring hospitalization per year in the NUCALA 100 mg SC, mepolizumab 75 mg IV, and placebo treatment groups were 0.03, 0.06 and 0.10, respectively.

Table 6  Summary of primary and secondary endpoints at Week 32¹

<table>
<thead>
<tr>
<th></th>
<th>NUCALA 100 mg SC N=194</th>
<th>Mepolizumab 75 mg IV N=191</th>
<th>Placebo N=191</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Frequency of Clinically Significant Exacerbations (Primary Endpoint)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exacerbation rate per year</td>
<td>0.83</td>
<td>0.93</td>
<td>1.74</td>
</tr>
<tr>
<td>Percent reduction vs. placebo</td>
<td>53%</td>
<td>47%</td>
<td>-</td>
</tr>
<tr>
<td>Rate ratio (95% CI)</td>
<td>0.47 (0.35, 0.64)</td>
<td>0.53 (0.40, 0.72)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>p-value²</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td><strong>Frequency of Clinically Significant Exacerbations Requiring Hospitalizations/Emergency Room Visits (Secondary Endpoint)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exacerbation rate per year</td>
<td>0.08</td>
<td>0.14</td>
<td>0.20</td>
</tr>
<tr>
<td>Percent reduction vs. placebo</td>
<td>61%</td>
<td>32%</td>
<td>-</td>
</tr>
<tr>
<td>Rate ratio (95% CI)</td>
<td>0.39 (0.18, 0.83)</td>
<td>0.68 (0.33, 1.41)</td>
<td></td>
</tr>
<tr>
<td>p-value²</td>
<td>0.015</td>
<td>0.299</td>
<td></td>
</tr>
</tbody>
</table>

¹Analysis was performed using a negative binomial model, which included covariates for treatment, use of maintenance oral corticosteroids, geographic region, number of exacerbations in the previous year, and baseline percentage of the predicted FEV₁.

²Type 1 error rate was controlled using a closed-testing procedure.
At Week 32, the mean change from baseline in pre-bronchodilator FEV₁ in the NUCALA 100 mg SC, mepolizumab 75 mg IV, and placebo treatment groups were 183 mL, 186 mL and 86 mL, respectively.

Health-related quality of life was measured using St. Georges Respiratory Questionnaire (SGRQ). At Week 32, mean changes from baseline in SGRQ scores in the NUCALA 100 mg SC, mepolizumab 75 mg IV, and placebo treatment groups were -16.0, -15.4 and -9.0, respectively.

**Steroid Reduction with mepolizumab Study (SIRIUS)**

**Study Design**

SIRIUS was a 24-week, randomized, placebo-controlled, double-blind, parallel group study that evaluated the effect of NUCALA 100 mg administered subcutaneously (SC) on reducing the requirement for maintenance oral corticosteroids (OCS) while maintaining asthma control in patients with severe eosinophilic asthma. A total 135 subjects were enrolled in the study (Table 4).

Subjects were required to have blood eosinophils of ≥150 cells/μL at initiation (within 6 weeks of dosing) or blood eosinophils of ≥300 cells/μL within 12 months of enrollment. Similar to MENSA, subjects had a documented requirement for high-dose ICS (or medium-dose ICS for adolescents) with an additional controller(s) in the previous year. Additionally, all subjects were required to be on regular maintenance treatment with OCS (5 to 35 mg/day prednisone or equivalent). No exacerbation history was required; however the majority of patients (84%) had a history of at least one exacerbation in the previous year.

The study included a run-in optimization phase of 3-8 weeks, in which subjects’ OCS dose was adjusted weekly, according to a pre-defined schedule, to establish the lowest dose of OCS required to maintain asthma control (hereafter referred to as baseline dose). Subjects were then randomized to receive either adjunctive NUCALA 100 mg SC or placebo treatment once every 4 weeks for 24 weeks. Reduction of the OCS dose occurred every 4 weeks (between Week 4 and Week 20) according to predefined schedule, and taking into account asthma control and adrenal insufficiency. The OCS dose was reduced until zero, or to the lowest possible dose required to maintain control during the 20 week OCS reduction phase. No further adjustment was made to the OCS dose following Week 20.

The primary endpoint was the percent reduction of OCS dose over Weeks 20 to 24 compared with the dose of OCS established during the run-in optimization phase at the start of the study. Predefined categories included percent reductions ranging from 90-100% reduction, to no decrease in the OCS dose from the end of the optimisation phase.

During the study, the percentage of patients who discontinued treatment and withdrew prematurely from the NUCALA 100 mg SC group and placebo group was 4% and 6%, respectively. The most common reason for discontinuation of treatment was due to adverse events (5% placebo, 4% NUCALA 100 mg SC).
Patient Demographics and Baseline Characteristics

Demographics and baseline characteristics were balanced between treatment groups (Table 7). With the exception of OCS, subjects continued their baseline asthma therapy throughout the trial (i.e. high-dose ICS (or medium-dose ICS for adolescents) with an additional controller(s)).

Table 7  Summary of patient demographics and baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>NUCALA 100 mg SC</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=69</td>
<td>N=66</td>
</tr>
<tr>
<td>Mean age in years (range)</td>
<td>50 (16 - 74)</td>
<td>50 (28 - 70)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25 (36)</td>
<td>36 (55)</td>
</tr>
<tr>
<td>Female</td>
<td>44 (64)</td>
<td>30 (45)</td>
</tr>
<tr>
<td>Mean duration of asthma in years (SD)</td>
<td>17.4 (11.8)</td>
<td>20.1 (14.4)</td>
</tr>
<tr>
<td>Mean % Predicted pre-bronchodilator FEV₁ (SD)</td>
<td>59.6 (17.0)</td>
<td>57.8 (18.5)</td>
</tr>
<tr>
<td>Geometric mean baseline blood eosinophil count (SD on log scale) - GL/L</td>
<td>0.25 (1.245)</td>
<td>0.23 (1.001)</td>
</tr>
<tr>
<td>Mean number of exacerbations in the previous year (SD)</td>
<td>3.3 (3.4)</td>
<td>2.9 (2.8)</td>
</tr>
<tr>
<td>Mean baseline daily OCS dose (mg)</td>
<td>12.4</td>
<td>13.2</td>
</tr>
</tbody>
</table>

Study Results

Subjects receiving NUCALA 100 mg SC achieved greater reductions in OCS dose compared to subjects receiving placebo, while maintaining asthma control (Table 8).

Table 8  Percent Reduction in OCS from Baseline at Weeks 20-24

<table>
<thead>
<tr>
<th>Percent Reduction in OCS from Baseline at Weeks 20-24 (%)</th>
<th>NUCALA 100 mg SC N= 69</th>
<th>Placebo N= 66</th>
</tr>
</thead>
<tbody>
<tr>
<td>90% - 100%</td>
<td>16 (23%)</td>
<td>7 (11%)</td>
</tr>
<tr>
<td>75% - &lt;90%</td>
<td>12 (17%)</td>
<td>5 (8%)</td>
</tr>
<tr>
<td>50% - &lt;75%</td>
<td>9 (13%)</td>
<td>10 (15%)</td>
</tr>
<tr>
<td>&gt;0% - &lt;50%</td>
<td>7 (10%)</td>
<td>7 (11%)</td>
</tr>
<tr>
<td>No decrease in OCS/lack of asthma control/withdrawal from treatment</td>
<td>25 (36%)</td>
<td>37 (56%)</td>
</tr>
</tbody>
</table>

For Weeks 20-24, 37 (54%) subjects in the NUCALA 100 mg SC group versus 22 (33%) subjects in the placebo group achieved ≥50% reduction in the daily OCS dose; 37 (54%) subjects in the NUCALA 100 mg SC group versus 21 (32%) subjects in the placebo group achieved a reduction in the daily OCS dose to ≤5.0 mg; and 10 (14%) subjects in the NUCALA 100 mg SC group achieved a total (100%) reduction in OCS dose to 0 mg compared with 5 (8%) subjects in the placebo group.
**Pediatrics**

In the double-blind placebo-controlled study MENSA (Table 4), there were 25 adolescents (12 to 17 years of age); 9 received mepolizumab 75 mg IV, 7 received NUCALA 100 mg SC, and 9 received placebo. Adolescents had a reduction in the rate of clinically significant exacerbation that trended in favour of mepolizumab.

Study 200363 was a multi-centre, open-label, uncontrolled, study that enrolled 36 children (6 to 11 years of age) with severe eosinophilic asthma. Subjects received 40 mg SC of NUCALA (for a weight < 40 kg) or 100 mg SC of NUCALA (for a weight ≥ 40 kg). The short-term phase (12 weeks) characterized the pharmacokinetics and pharmacodynamics of mepolizumab in children (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics and Pharmacodynamics). Following a treatment interruption of 8 weeks, the long-term phase (52 weeks) assessed safety and tolerability.

The efficacy of NUCALA in children (6 to 11 years of age) for a 40 mg SC dose is extrapolated from efficacy in adults and adolescents with support from population pharmacokinetic analyses and pharmacodynamic analyses. The disease course, pathophysiology, and drug effects in children are assumed to be sufficiently consistent to adults and adolescents at the same exposure levels.

**Eosinophilic Granulomatosis with Polyangiitis**

**Study Design**

The efficacy and safety of mepolizumab as an adjunct to oral corticosteroids for the treatment of patients with EGPA was evaluated in a phase III, multi-centre, randomized, double-blind, placebo-controlled study of 52 weeks duration in 136 subjects aged 18 years and older. Subjects received 300 mg of NUCALA or placebo administered subcutaneously once every 4 weeks, while maintaining stable oral corticosteroid therapy (Table 9). Starting at Week 4, oral corticosteroid dose could be tapered during the treatment period at the discretion of the investigator. The co-primary endpoints were: 1) the total accrued duration of remission over the 52-week treatment period, defined as Birmingham Vasculitis Activity Score (BVAS) = 0 (no active vasculitis) plus oral corticosteroid dose ≤4 mg/day (prednisolone/prednisone); and 2) the proportion of subjects in remission at both Week 36 and Week 48 of treatment. Relapse of disease was defined as worsening or persistence of active disease since the last visit warranting: i) an increased dose of OCS therapy (>4 mg/day); OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalization related to EGPA worsening. Worsening of active disease was characterized by: i) active vasculitis (BVAS >0); OR ii) active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR iii) active nasal and/or sinus disease with a corresponding worsening in at least one of the sino-nasal symptom questions.
Table 9  Summary of trial design for MEA115921

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEA115921</td>
<td>52-week, multi-centre, randomised, double-blind, placebo-controlled study of mepolizumab in subjects with a history of relapsing or refractory EGPA on stable oral corticosteroid therapy with or without concomitant stable immunosuppressant therapy(^a).</td>
<td>NUCALA 300 mg SC Placebo</td>
<td>n=68</td>
<td>n=68</td>
<td>Female: 80 (59%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Duration: 52 weeks</td>
<td>Total: 136</td>
<td>48.5 (20-71)</td>
<td>Male: 56 (41%)</td>
</tr>
</tbody>
</table>

SC = subcutaneous; EGPA = Eosinophilic Granulomatosis with Polyangiitis.
\(^a\) Excluding cyclophosphamide.

**Patient Demographics and Baseline Characteristics**
The demographics and baseline characteristics of subjects in this trial are provided in Table 10.
Table 10  Summary of patient demographics and baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>NUCALA 300 mg SC</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=68</td>
<td>N=68</td>
</tr>
<tr>
<td>Mean age (y)</td>
<td>48.7</td>
<td>48.2</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>42 (62)</td>
<td>38 (56)</td>
</tr>
<tr>
<td>White, n (%)</td>
<td>64 (94)</td>
<td>61 (90)</td>
</tr>
<tr>
<td>Duration (y) of EGPA, mean (SD)</td>
<td>5.24 (4.398)</td>
<td>5.85 (4.855)</td>
</tr>
<tr>
<td>History of ≥1 confirmed relapse in past 2 years, n (%)</td>
<td>51 (75)</td>
<td>49 (72)</td>
</tr>
</tbody>
</table>

### History/presence of Asthma plus

<table>
<thead>
<tr>
<th></th>
<th>NUCALA 300 mg SC</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eosinophilia (&gt;1.0x10^9/L), n (%)</td>
<td>68 (100)</td>
<td>68 (100)</td>
</tr>
<tr>
<td>Sino-nasal abnormality</td>
<td>64 (94)</td>
<td>64 (94)</td>
</tr>
<tr>
<td>Pulmonary infiltrates, non-fixed</td>
<td>50 (74)</td>
<td>48 (71)</td>
</tr>
<tr>
<td>Biopsy evidence¹</td>
<td>25 (37)</td>
<td>31 (46)</td>
</tr>
<tr>
<td>Neuropathy, Mono or Poly²</td>
<td>32 (47)</td>
<td>24 (35)</td>
</tr>
<tr>
<td>ANCA positive (MPO or PR3)</td>
<td>13 (19)</td>
<td>13 (19)</td>
</tr>
<tr>
<td>Cardiomyopathy³</td>
<td>13 (19)</td>
<td>7 (10)</td>
</tr>
<tr>
<td>Palpable purpura</td>
<td>9 (13)</td>
<td>8 (12)</td>
</tr>
<tr>
<td>Alveolar hemorrhage⁴</td>
<td>3 (4)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Glomerulonephritis⁵</td>
<td>1 (1)</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Refractory disease, n (%)</th>
<th>NUCALA 300 mg SC</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrence of EGPA symptoms, n (%)</td>
<td>34 (50)</td>
<td>40 (59)</td>
</tr>
<tr>
<td>Failed induction treatment, n (%)</td>
<td>33 (49)</td>
<td>35 (51)</td>
</tr>
</tbody>
</table>

| Baseline BVAS, median (range)     | 1 (0-22)         | 2 (0-19) |
| Baseline oral corticosteroid daily dose (mg), median (range) | 12 (7.5-40) | 11 (7.5-50.0) |

<table>
<thead>
<tr>
<th>Receiving immunosuppressive therapy, n (%)</th>
<th>NUCALA 300 mg SC</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>41 (60)</td>
<td>31 (46)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Baseline ACQ-6 Score Category⁶,⁷, n (%)</th>
<th>NUCALA 300 mg SC</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤0.75</td>
<td>23 (34)</td>
<td>19 (28)</td>
</tr>
<tr>
<td>&gt;0.75 to &lt;1.5</td>
<td>19 (28)</td>
<td>21 (31)</td>
</tr>
<tr>
<td>≥1.5</td>
<td>26 (38)</td>
<td>28 (41)</td>
</tr>
</tbody>
</table>

¹ A biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatosus inflammation

² Motor deficit or nerve conduction abnormality

³ Established by echocardiography or MRI

⁴ Determined by bronchoalveolar lavage

⁵ Hematuria, red blood cell casts, proteinuria

⁶ ACQ-6 score ≤0.75 = well controlled asthma, >0.75 to <1.5 = some lack of asthma control, ≥1.5 = not well controlled asthma.

⁷ Summarized post-hoc.

a Prednisone or prednisolone equivalent.

b Excluding cyclophosphamide.

ANCA = anti-neutrophil cytoplasmic antibodies; EGPA = eosinophilic granulomatosis with polyangiitis; SD = standard deviation;
MPO = myeloperoxidase (ANCA-MPO); PR3 = proteinase 3 (ANCA-PR3).

**Study Results**

**Remission**

Subjects receiving 300 mg of NUCALA achieved a significantly greater accrued time in remission compared with placebo (odds ratio: 5.9 [95% CI: 2.7, 13.0]; p<0.001). Additionally, a significantly larger proportion of subjects receiving 300 mg of NUCALA achieved remission at both Week 36 and Week 48 compared with placebo (odds ratio: 16.7 [95% CI: 3.6, 77.7]; p<0.001) (Table 11).

**Table 11 Analyses of Co-Primary Endpoints**

<table>
<thead>
<tr>
<th>Accrued duration of remission over 52 weeks</th>
<th>Number (%) of Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NUCALA 300 mg n = 68</td>
</tr>
<tr>
<td>0 weeks</td>
<td>32 (47)</td>
</tr>
<tr>
<td>&gt;0 to &lt;12 weeks</td>
<td>8 (12)</td>
</tr>
<tr>
<td>12 to &lt;24 weeks</td>
<td>9 (13)</td>
</tr>
<tr>
<td>24 to &lt;36 weeks</td>
<td>10 (15)</td>
</tr>
<tr>
<td>≥36 weeks</td>
<td>9 (13)</td>
</tr>
<tr>
<td>Odds ratio (mepolizumab/placebo)(a)</td>
<td>5.91(b)</td>
</tr>
<tr>
<td>95% CI</td>
<td>2.68, 13.03</td>
</tr>
<tr>
<td>(P) value</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Proportion of subjects in remission at Weeks 36 and 48**

<table>
<thead>
<tr>
<th>Subjects in remission at Weeks 36 and 48 (%)</th>
<th>Number (%) of Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NUCALA 300 mg n = 68</td>
</tr>
<tr>
<td>Odds ratio (mepolizumab/placebo)(a)</td>
<td>16.74</td>
</tr>
<tr>
<td>95% CI</td>
<td>3.61, 77.56</td>
</tr>
<tr>
<td>(P) value</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

\(a\) An odds ratio >1 favors mepolizumab.

\(b\) Obtained using a proportional odds regression model for ordered categorical data (incremental 12-week durations).

Statistically significant differences in favour of mepolizumab for these endpoints were also demonstrated by the European League Against Rheumatism (EULAR) definition of remission (i.e., BVAS = 0 plus oral corticosteroid dose ≤7.5 mg/day (prednisolone/prednisone)).

A larger proportion of subjects receiving 300 mg of NUCALA (n=13; 19%) achieved remission within the first 24 weeks of treatment and remained in remission for the remainder of the 52-week treatment period compared with placebo (n=1; 1%).

**Relapse**

The time to first relapse was significantly longer for subjects receiving 300 mg of NUCALA compared with placebo (hazard ratio: 0.32 [95% CI: 0.21, 0.50]; p<0.001) (Figure 2). The incidence and number of each potential cause for relapse (i.e., vasculitis, asthma, sino-nasal)
were lower in subjects treated with mepolizumab compared with placebo.

**Figure 2 Kaplan-Meier Plot of Time to First Relapse**

![Kaplan-Meier Plot](image)

**Oral Corticosteroid Reduction**

Subjects receiving 300 mg of NUCALA had a significantly greater reduction in average daily oral corticosteroid dose compared with subjects receiving placebo during Weeks 48 to 52 (odds ratio: 0.20 [95% CI 0.09, 0.41]; p<0.001) (Table 12).

**Table 12 Average Daily Oral Corticosteroid Dose during Weeks 48 to 52**

<table>
<thead>
<tr>
<th>Average Daily Oral Corticosteroid Dose</th>
<th>NUCALA 300 mg Subcutaneous n = 68</th>
<th>Placebo n = 68</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>12 (18)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>&gt;0 to (\leq 4.0 \text{ mg})</td>
<td>18 (26)</td>
<td>3 (4)</td>
</tr>
<tr>
<td>&gt;4.0 to (\leq 7.5 \text{ mg})</td>
<td>10 (15)</td>
<td>18 (26)</td>
</tr>
<tr>
<td>&gt;7.5 mg</td>
<td>28 (41)</td>
<td>45 (66)</td>
</tr>
</tbody>
</table>

Comparison: mepolizumab/placebo

- Odds ratio: 0.20
- 95% CI: 0.09, 0.41
- \(P\) value: <0.001

*a* Analyzed using a proportional odds model with covariates of treatment group, baseline oral corticosteroid daily dose, baseline BVAS, and region. An odds ratio <1 favors mepolizumab.
TOXICOLOGY

Intravenous and subcutaneous administrations to monkeys were associated with reductions in peripheral and lung eosinophil counts, with no toxicological findings. Eosinophils have been associated with immune system responses to some parasitic infections. Studies conducted in mice treated with anti-IL-5 antibodies or genetically deficient in IL-5 or eosinophils have not shown impaired ability to clear parasitic infections.

Carcinogenesis, Mutagenesis and Impairment of Fertility and Reproduction

Long-term animal studies have not been performed to evaluate the carcinogenic potential of mepolizumab. The mutagenic potential of mepolizumab was not evaluated. The role of IL-5 and eosinophils in tumor surveillance is poorly characterized. However, there is no evidence of defective tumor surveillance in IL-5–deficient or eosinophil-deficient mice.

There was no effect of anti-IL-5 antibodies on male and female mice on mating, fertility, and gonadal function or on early embryonic or embryofetal development in pregnant females. Studies in mice did not include a littering or functional F1 assessment. In cynomolgus monkeys, mepolizumab had no effect on pregnancy or on embryonic/fetal and postnatal development (including immune function) of the offspring. Examinations for internal or skeletal malformations were not performed. Data in monkeys demonstrate that mepolizumab crosses the placenta. Concentrations of mepolizumab were approximately 2.4 times higher in infants than in mothers for several months post-partum and did not affect the immune system of the infants. Mepolizumab was excreted into the milk of cynomolgus monkeys at concentrations that were less than 0.5% of those detected in plasma and there were no post-natal developmental effects in breastfed monkey offspring.
REFERENCES


READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

PrNUCALA

[new-ka' la]

Mepolizumab for Injection
100 mg/mL lyophilized powder for subcutaneous injection

Read this carefully before you start taking NUCALA and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about NUCALA.

What is NUCALA used for?

**Severe Eosinophilic Asthma**
NUCALA (mepolizumab for injection) is a prescription medicine used in addition to other asthma medicines to treat adults, adolescents (12-17 years of age), and children (6-11 years of age) with severe eosinophilic asthma, whose asthma is not controlled with their current asthma medicines, such as high-dose inhalers. Severe eosinophilic asthma is a type of severe asthma in which there is a presence of eosinophils (a type of white blood cell). Eosinophils are associated with inflammation of the airways that can cause your asthma to get worse or can increase the number of asthma attacks. NUCALA helps prevent the number of asthma attacks.

NUCALA is not used to treat acute asthma symptoms, such as a sudden asthma attack.

**Eosinophilic Granulomatosis and Polyangiitis (EGPA)**
EGPA is a condition where people have inflammation of the blood vessels (vasculitis) due to too many eosinophils (a type of white blood cell) in the blood and tissues. EGPA most commonly affects the lungs and sinuses but often also affects other organs including the skin, heart, kidneys, nerves or bowels. The most common symptoms include extreme fatigue, muscle and joint pain, weight loss, sinonasaal symptoms, and breathlessness.

In adults, NUCALA, used in addition to corticosteroids, can reduce EGPA symptoms and delay flare-up of these symptoms. NUCALA can also help reduce the daily dose of corticosteroids you need to control your symptoms.

**How does NUCALA work?**
NUCALA contains the active substance, mepolizumab, a monoclonal antibody that works by blocking a specific protein called interleukin-5. By blocking the action of interleukin-5, NUCALA limits the production of more eosinophils from the bone marrow and lowers the number of eosinophils in the blood, lungs and tissues.

**What are the ingredients in NUCALA?**
Medicinal ingredients: The active substance is mepolizumab.
Non-medicinal ingredients: The other ingredients are polysorbate 80, sodium phosphate dibasic heptahydrate, and sucrose.

**NUCALA comes in the following dosage form:**
Lyophilized powder for subcutaneous injection; each single-use vial contains 144 mg of mepolizumab (100 mg/mL when reconstituted).

**Do not use NUCALA if:**
- you are allergic to mepolizumab or any of the other ingredients of this medicine. **Talk to your doctor** about whether this may apply to you.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you use NUCALA.**

- Medicines of this type (monoclonal antibodies) can cause severe allergic reactions when injected into the body (see **What are the possible side effects from using NUCALA?**). If you have had a similar reaction before, tell your doctor before you are given NUCALA.

- NUCALA does not treat acute asthma symptoms, such as a sudden asthma attack. Therefore, NUCALA should not be used to treat such symptoms.

- Tell your doctor if your asthma symptoms remain uncontrolled or get worse while being treated with NUCALA.

- Tell your doctor if you are taking corticosteroids or other medicines for the treatment of asthma or Eosinophilic Granulomatosis with Polyangiitis. **Do not suddenly stop taking** your corticosteroids or other medicines once you have started NUCALA. Corticosteroids must be stopped gradually, under the supervision of your doctor.

**Talk about any health conditions or problems you may have, including:**

- If you have an existing parasitic infection, live in a region where infections caused by parasites are common, or if you are travelling to such a region. NUCALA may weaken your resistance to such infections. Parasitic infections should be treated prior to starting treatment with NUCALA.

- If you have or have not had chickenpox (varicella) or shingles, or if you have or have not received a chickenpox or shingles vaccine.

**Pregnancy and breast-feeding:**

- If you are pregnant, think you may be pregnant, or are planning to become pregnant, **tell your doctor** before using this medicine. You should not use this medicine if you are pregnant, unless this is considered necessary by your doctor. There is a pregnancy registry for women with severe eosinophilic asthma who receive NUCALA while pregnant. The purpose of the registry is to collect information about the health of you and your baby. You can talk to your healthcare provider about how to take part in this registry or you can get
more information and register by calling 1-877-311-8972 or go to http://mothertobaby.org/asthma/.

- If you become pregnant while being treated with NUCALA or within 4 months of stopping treatment with NUCALA, tell your doctor immediately.

- It is not known whether the ingredients of NUCALA can pass into breast milk. If you are breastfeeding or plan to breastfeed, you must tell your doctor before being treated with NUCALA.

Other warnings you should know about:
NUCALA should not be given to children under 6 years of age for the treatment of severe eosinophilic asthma and should not be given to children and adolescents under 18 years of age for the treatment of EGPA.

Tell your healthcare professional about all the medicines you take or have recently taken, including drugs, or medicines obtained without a prescription (vitamins, minerals, natural supplements or alternative medicines).

How to take NUCALA:
NUCALA is given to you as an injection just under the skin (subcutaneously) by a healthcare professional, who is experienced in the monitoring and treatment of signs and symptoms of allergic reactions.

Usual dose:

**Severe Eosinophilic Asthma**

**Adults and adolescents (12 years of age and older)**
The recommended dose of NUCALA for severe eosinophilic asthma in adults and adolescents is 100 mg, given as 1 injection under the skin (subcutaneous) every four weeks.

**Children (6 to 11 years of age)**
The recommended dose of NUCALA for severe eosinophilic asthma for children is 40 mg, given as 1 injection under the skin (subcutaneous) every four weeks. This dose is prepared using the NUCALA lyophilized powder for subcutaneous injection.

**Eosinophilic Granulomatosis with Polyangiitis**
The recommended dose of NUCALA for EGPA in adults is 300 mg, given as 3 injections under the skin (subcutaneous) every four weeks.

Do not stop receiving injections of NUCALA unless advised by your doctor. Interrupting or stopping the treatment with NUCALA may cause your symptoms to become worse or occur more frequently. If your symptoms get worse when being treated with NUCALA, immediately tell your doctor.
**Overdose:**

In case of drug overdose, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

**Missed Dose:**

If a dose of NUCALA is missed, contact your healthcare professional, such as doctor or nurse, as soon as possible to re-schedule your appointment.

**What are possible side effects from using NUCALA?**

Like all medicines, NUCALA can cause side effects, although not everybody gets them. The side effects caused by NUCALA are usually mild to moderate but can occasionally be serious.

These are not all the possible side effects that you may feel when taking NUCALA. If you experience any side effects not listed here, contact your healthcare professional.

Allergic or Allergic-like reactions

Some people may have allergic or allergic-like reactions that may be severe (e.g. anaphylaxis). These reactions often occur within minutes to hours after the injection, but sometimes symptoms can start several days later. You may experience this type of reaction even if it is not your first injection of NUCALA.

Symptoms can include:

- becoming very wheezy, cough, difficulty breathing, chest tightness
- fainting, dizziness, suddenly feeling weak or lightheaded (due to a drop in blood pressure)
- swelling of your eyelids, face, lips, tongue, mouth, and other areas of the body (angioedema) skin rash, hives, redness

Stop taking NUCALA and seek medical attention immediately if you think you (or your child) may be having a reaction.

If you (or your child) may have had a similar reaction before (see also To help avoid side effects and ensure proper use, talk to your healthcare professional before you take NUCALA), tell your doctor before you are given NUCALA.

Very common side effects (may affect more than 1 in 10 people):

- Headache
- Joint Pain
- Sinus Infection
- Cough, sore throat, runny nose, nasal congestion (common cold, chest cold, upper respiratory tract infection)
- Diarrhea
- Vomiting
- Back pain
• Rash
• Neck pain
• Mouth and/or throat pain
• Injection site reaction (pain, redness, swelling, itching, and burning sensation of the skin near where the injection was given)
• Flu (influenza)
• Difficulty breathing (wheezing, cough, shortness of breath)

Common side effects (may affect up to 1 in 10 people):
• Nausea
• Constipation
• Bleeding nose (epistaxis)
• Eye or ear infection
• Skin infection (impetigo)
• Pain
• Anger (aggression)
• Dizziness
• Throat redness
• Rash (atopic dermatitis)
• Sore throat (pharyngitis)
• Congestion, cough, discomfort, fever (lower respiratory tract infection)
• Stuffy and/or runny nose, sneezing (nasal congestion, rhinitis)
• Stomach pain or discomfort in the upper area of the stomach (upper abdominal pain)
• Itchy red patches on the skin (eczema)
• Urinary tract infection (blood in urination, painful and frequent urination, fever, pain in lower back)
• High temperature (fever)
• Muscle and/or bone pain
• Sensation of spinning or feeling off balance, dizziness (vertigo)
• Lack of energy, muscle weakness
• Sensation of tingling and/or numbness (paraesthesia)
• Blurry vision

Tell your healthcare professional immediately if you get any of these symptoms, or if you notice any side effects not listed in this leaflet.

<table>
<thead>
<tr>
<th>Serious side effects and what to do about them</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptom / effect</strong></td>
<td><strong>Only if severe</strong></td>
<td><strong>In all cases</strong></td>
</tr>
<tr>
<td>Sudden, severe allergic reaction (e.g. anaphylaxis):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• skin rash (hives) or redness</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NUCALA – Product Monograph  Page 46 of 69
### Serious side effects and what to do about them

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>• swelling, sometimes of the face or mouth (angioedema)</td>
<td>Only if severe</td>
<td></td>
</tr>
<tr>
<td>• becoming very wheezy, coughing or having difficulty breathing</td>
<td>In all cases</td>
<td></td>
</tr>
<tr>
<td>• suddenly feeling weak or light headed (may lead to collapse or loss of consciousness)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting ([https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html)) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

**NOTE:** Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

### Storage:

- Keep out of the sight and reach of children.
- Do not use this medicine after the expiry date that is stated on the label.
- The expiry date refers to the last day of the stated month.
- Store in the original carton to protect from light.
- Store below 25°C. Discard unused drug if reconstituted more than 8 hours.
- Do not shake or freeze.

### If you want more information about NUCALA:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website](https://www.canada.ca); the manufacturer’s website [www.gsk.ca](http://www.gsk.ca); or, by calling 1-800-387-7374.

This leaflet was prepared by GlaxoSmithKline Inc.

**Last Revised:** March 12, 2020
What is NUCALA used for?

**Severe Eosinophilic Asthma**

NUCALA (mepolizumab injection) is a prescription medicine used in addition to other asthma medicines to treat adults and adolescents (12-17 years of age) with severe eosinophilic asthma, whose asthma is not controlled with their current asthma medicines, such as high-dose inhalers. Severe eosinophilic asthma is a type of severe asthma in which there is a presence of eosinophils (a type of white blood cell). Eosinophils are associated with inflammation of the airways that can cause your asthma to get worse or can increase the number of asthma attacks. NUCALA helps prevent the number of asthma attacks.

NUCALA is not used to treat acute asthma symptoms, such as a sudden asthma attack.

**Eosinophilic Granulomatosis and Polyangiitis (EGPA)**

EGPA is a condition where people have inflammation of the blood vessels (vasculitis) due to too many eosinophils (a type of white blood cell) in the blood and tissues. EGPA most commonly affects the lungs and sinuses but often also affects other organs including the skin, heart, kidneys, nerves or bowels. The most common symptoms include extreme fatigue, muscle and joint pain, weight loss, sinonasal symptoms, and breathlessness.

NUCALA, used in addition to corticosteroids, can reduce EGPA symptoms and delay flare-up of these symptoms. NUCALA can also help reduce the daily dose of corticosteroids you need to control your symptoms.

**How does NUCALA work?**

NUCALA contains the active substance, mepolizumab, a monoclonal antibody that works by blocking a specific protein called interleukin-5. By blocking the action of interleukin-5, NUCALA limits the production of more eosinophils from the bone marrow and lowers the number of eosinophils in the blood, lungs and tissues.
What are the ingredients in NUCALA?
Medicinal ingredients: The active substance is mepolizumab.
Non-medicinal ingredients: The other ingredients are citric acid monohydrate, EDTA disodium dihydrate, polysorbate 80, sodium phosphate dibasic heptahydrate, and sucrose.

NUCALA comes in the following dosage form:
A solution for subcutaneous injection in pre-filled autoinjector or safety syringe. Each autoinjector or safety syringe contains 100 mg/mL of mepolizumab.

Do not use NUCALA if:
- you are allergic to mepolizumab or any of the other ingredients of this medicine. Talk to your doctor about whether this may apply to you.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you use NUCALA.
- Medicines of this type (monoclonal antibodies) can cause severe allergic reactions when injected into the body (see What are the possible side effects from using NUCALA?). If you have had a similar reaction before, tell your doctor before you are given NUCALA.
- NUCALA does not treat acute asthma symptoms, such as a sudden asthma attack. Therefore, NUCALA should not be used to treat such symptoms.
- Tell your doctor if your asthma symptoms remain uncontrolled or get worse while being treated with NUCALA.
- Tell your doctor if you are taking corticosteroids or other medicines for the treatment of asthma or Eosinophilic Granulomatosis with Polyangiitis. Do not suddenly stop taking your corticosteroids or other medicines once you have started NUCALA. Corticosteroids must be stopped gradually, under the supervision of your doctor.

Talk about any health conditions or problems you may have, including:
- If you have an existing parasitic infection, live in a region where infections caused by parasites are common, or if you are travelling to such a region. NUCALA may weaken your resistance to such infections. Parasitic infections should be treated prior to starting treatment with NUCALA.
- If you have or have not had chickenpox (varicella) or shingles, or if you have or have not received a chickenpox or shingles vaccine.

Pregnancy and breast-feeding:
- If you are pregnant, think you may be pregnant, or are planning to become pregnant, tell your doctor before using this medicine. You should not use this medicine if you are pregnant, unless this is considered necessary by your doctor. There is a pregnancy registry for women with severe eosinophilic asthma who receive NUCALA while pregnant. The purpose of the registry is to collect information about the health of you and your baby. You
can talk to your healthcare provider about how to take part in this registry or you can get more information and register by calling 1-877-311-8972 or go to http://mothertobaby.org/asthma/.

- If you become pregnant while being treated with NUCALA or within 4 months of stopping treatment with NUCALA, tell your doctor immediately.

- It is not known whether the ingredients of NUCALA can pass into breast milk. **If you are breastfeeding or plan to breastfeed, you must tell your doctor before being treated with NUCALA.**

**Other warnings you should know about:**
NUCALA should not be given to children under 6 years of age for the treatment of severe eosinophilic asthma and should not be given to children and adolescents under 18 years of age for the treatment of EGPA. The pre-filled autoinjector or pre-filled safety syringe should not be used in children.

Tell your healthcare professional about all the medicines you take or have recently taken, including drugs, or medicines obtained without a prescription (vitamins, minerals, natural supplements or alternative medicines).

**How to administer NUCALA:**
NUCALA is a solution for injection in a single-dose pre-filled autoinjector or a single-dose pre-filled safety syringe, which can be given by a healthcare professional, you, or your caregiver. Your healthcare professional will decide if you or your caregiver can inject NUCALA. If appropriate, they will provide training to show you or your caregiver the correct way to give the injections before you use NUCALA. Read the Instructions for Use (IFU) that comes with NUCALA autoinjector or safety syringe for instructions about the correct way to give yourself an injection.

- NUCALA is given by injection under the skin (subcutaneously).

- You can inject NUCALA under your skin in your stomach area (abdomen) or upper leg (thigh). Your caregiver can also inject NUCALA into your upper arm. You should not give injections into areas where the skin is tender, bruised, red, or hard.

**Usual dose:**

**Severe Eosinophilic Asthma**
**Adults and adolescents (12 years of age and older)**
The recommended dose of NUCALA for severe eosinophilic asthma in adults and adolescents is 100 mg, given as 1 injection under the skin (subcutaneous) every four weeks.

**Children (6 to 11 years of age)**
Only the lyophilized powder for subcutaneous injection can provide the correct dose for children. The pre-filled autoinjector or pre-filled safety syringe should not be used in children.
**Eosinophilic Granulomatosis with Polyangiitis**

The recommended dose of NUCALA for EGPA in adults is 300 mg, given as 3 injections under the skin (subcutaneous) every four weeks.

Do not stop using NUCALA unless advised by your doctor. Interrupting or stopping the treatment with NUCALA may cause your symptoms to become worse or occur more frequently. If your symptoms get worse when being treated with NUCALA, immediately tell your doctor.

**Overdose:**

In case of drug overdose, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

**Missed Dose:**

If you or your caregiver forget to give an injection of NUCALA:

You should inject the next dose of NUCALA as soon as you remember. Then, you can resume dosing on the usual day of administration. If you do not notice that you have missed a dose until it is already time for your next dose, then just inject the next dose as planned. If you are not sure what to do, ask your healthcare professional, such as doctor, pharmacist or nurse.

**What are possible side effects from using NUCALA?**

Like all medicines, NUCALA can cause side effects, although not everybody gets them. The side effects caused by NUCALA are usually mild to moderate but can occasionally be serious.

These are not all the possible side effects that you may feel when taking NUCALA. If you experience any side effects not listed here, contact your healthcare professional.

Allergic or Allergic-like reactions

Some people may have allergic or allergic-like reactions that may be severe (e.g. anaphylaxis). These reactions often occur within minutes to hours after the injection, but sometimes symptoms can start several days later. You may experience this type of reaction even if it is not your first injection of NUCALA.

Symptoms can include:

- becoming very wheezy, cough, difficulty breathing, chest tightness
- fainting, dizziness, suddenly feeling weak or lightheaded (due to a drop in blood pressure)
- swelling of your eyelids, face, lips, tongue, mouth, and other areas of the body (angioedema) skin rash, hives, redness

Stop taking NUCALA and seek medical attention immediately if you think you (or your child) may be having a reaction.
If you (or your child) may have had a similar reaction before (see also To help avoid side effects and ensure proper use, talk to your healthcare professional before you take NUCALA), tell your doctor before you are given NUCALA.

Very common side effects (may affect more than 1 in 10 people):
- Headache
- Joint Pain
- Sinus Infection
- Cough, sore throat, runny nose, nasal congestion (Upper respiratory tract infection)
- Diarrhea
- Vomiting
- Back pain
- Rash
- Neck pain
- Mouth and/or throat pain
- Injection site reaction (pain, redness, swelling, itching, and burning sensation of the skin near where the injection was given)

Common side effects (may affect up to 1 in 10 people):
- Sore throat (pharyngitis)
- Congestion, cough, discomfort, fever (lower respiratory tract infection)
- Stuffy nose (nasal congestion)
- Stomach pain or discomfort in the upper area of the stomach (upper abdominal pain)
- Itchy red patches on the skin (eczema)
- Urinary tract infection (blood in urination, painful and frequent urination, fever, pain in lower back)
- High temperature (fever)
- Muscle and/or bone pain
- Sensation of spinning or feeling off balance, dizziness (Vertigo)
- Lack of energy, muscle weakness
- Sensation of tingling and/or numbness (Paraesthesia)
- Blurry vision

Tell your healthcare professional immediately if you get any of these symptoms, or if you notice any side effects not listed in this leaflet.

<table>
<thead>
<tr>
<th>Serious side effects and what to do about them</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom / effect</td>
<td>Talk to your healthcare professional</td>
</tr>
<tr>
<td>Sudden, severe allergic reaction (e.g. anaphylaxis):</td>
<td>Only if severe</td>
</tr>
<tr>
<td>-skin rash (hives) or redness</td>
<td></td>
</tr>
</tbody>
</table>
Serious side effects and what to do about them

| -swelling, sometimes of the face or mouth (angioedema) |  |
| -becoming very wheezy, coughing or having difficulty breathing |  |
| -suddenly feeling weak or light headed (may lead to collapse or loss of consciousness) |  |

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

**Reporting Side Effects**
You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

**Storage:**
- Keep out of the sight and reach of children.
- Do not use this medicine after the expiry date that is stated on the label. The expiry date refers to the last day of the stated month.
- Store in the original carton to protect from light.
- Store refrigerated (2°C to 8°C).
- If necessary, can be removed from the refrigerator and kept in the unopened carton for up to 7 days at below 30°C. **Discard if the unopened carton is left out of the refrigerator for more than 7 days.**
- The pre-filled autoinjector or safety syringe must be administered within 8 hours once the carton is opened. Discard if not administered within 8 hours.
- Do not shake or freeze.

**If you want more information about NUCALA:**
- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website; the manufacturer’s website www.gsk.ca; or, by calling 1-800-387-7374.

This leaflet was prepared by GlaxoSmithKline Inc.
NUCALA (mepolizumab injection)

INSTRUCTIONS FOR USE - PRE-FILLED AUTOINJECTOR

Administer once every four weeks

These INSTRUCTIONS FOR USE should be read together with the rest of the PATIENT MEDICATION INFORMATION in your NUCALA package. Contact your healthcare professional if you have any questions about NUCALA.

Follow these instructions on how to use the pre-filled autoinjector. Failure to follow these instructions may affect proper function of the pre-filled autoinjector. You should also receive training on how to use the pre-filled autoinjector. NUCALA pre-filled autoinjector is for use under the skin only (subcutaneous).

How to store NUCALA

- Keep refrigerated before use.
- Do not freeze.
- Keep in the carton to protect from light.
- Keep out of the sight and reach of children.
- If necessary, the pre-filled autoinjector may be kept at below 30°C, for no more than 7 days, when stored in the original carton. Throw it away if it has not been used within 7 days.
- The autoinjector must be used within 8 hours once the carton is opened. Discard if not used within 8 hours.
- Do not store it above 30°C.

Before you use NUCALA

The pre-filled autoinjector should be used only once and then discarded.

- Do not share your NUCALA pre-filled autoinjector with another person.
- Do not shake the autoinjector.
- Do not use the autoinjector if dropped onto a hard surface.
- Do not use the autoinjector if it appears damaged.
- Do not remove the needle cap until just before your injection.
Gather Supplies

Find a comfortable, well-lit and clean surface. Make sure you have within reach:

- NUCALA pre-filled autoinjector
- Alcohol wipe (not included)
- Gauze pad or cotton ball (not included)

**Do not** perform the injection if you do not have all these.
1. Prepare the NUCALA autoinjector

- Take the carton out of the refrigerator. Check the security seals are not broken.
- Remove the tray from the carton.
- Peel back the film cover from the tray.
- Holding the middle of the autoinjector, carefully take it out of the tray.
- Place the autoinjector on a clean, flat surface, at room temperature, away from direct sunlight and out of the reach of children.

**Do not** use the autoinjector if the security seal on the carton is broken.
**Do not** remove the needle cap at this stage.
2. Inspect and wait 30 minutes before use

- Check the expiry date on the label of the autoinjector.
- Look in the inspection window to check that the liquid is clear (free from cloudiness or particles) and colourless or pale yellow to pale brown.
- It is normal to see one or more air bubbles.
- Wait 30 minutes (and no more than 8 hours) before use.

**Do not** use if the expiry date has passed.
**Do not** warm the autoinjector in a microwave, hot water, or direct sunlight.
**Do not** inject if the solution looks cloudy or discoloured, or has particles.
**Do not** use the autoinjector if left out of the carton for more than 8 hours.
**Do not** remove the needle cap during this step.
3. Choose your injection site

- You can inject NUCALA into your thighs or abdomen.
- If someone else gives you the injection, they can also use your upper arm.
- If you need more than one injection to complete your dose then leave at least 5 cm (2 inches) between each injection site.

**Do not** inject where your skin is bruised, tender, red or hard.
**Do not** inject within 5 cm (2 inches) of your navel (belly button).

4. Clean your injection site

- Wash your hands with soap and water.
- Clean your injection site by wiping the skin with an alcohol wipe and allowing the skin to air dry.

**Do not** touch your injection site again until you have finished your injection.
5. Remove the clear needle cap

- Remove the clear needle cap from the autoinjector by firmly pulling it straight off.
- Do not worry if you see a drop of liquid at the end of the needle. This is normal.
- Inject straight after removing the needle cap, and always within 5 minutes.

**Do not** touch the yellow needle guard with your fingers. This could activate the autoinjector too soon and may cause a needle injury.

After removal, do not put the needle cap back onto the autoinjector, as it may accidentally start the injection.

6. Start your injection

- Hold the autoinjector with its inspection window facing towards you, so you can see it, and with the yellow needle guard facing down.
- Place the autoinjector straight onto your injection site with the yellow needle guard flat against the surface of your skin, as shown.
• To start your injection, push the autoinjector down all the way and keep it held down against your skin. The yellow needle guard will slide up into the autoinjector.
• You should hear the 1st “click” to tell you your injection has started.
• The yellow indicator will move down through the inspection window as you receive your dose.

**Do not** lift the autoinjector from your skin at this stage, as that may mean you don’t get your full dose of medicine. Your injection may take up to 15 seconds to complete.
**Do not** use the autoinjector if the yellow needle guard doesn’t slide up as described. Dispose of it (see **Dispose of the used autoinjector** step), and start again with a new autoinjector.

7. **Hold the autoinjector in place to complete your injection**

- Continue to hold the autoinjector down until you hear the 2nd “click”, and the stopper and yellow indicator have stopped moving and fill the inspection window.
- Continue to hold the autoinjector in place while you count to 5. Then lift the autoinjector away from your skin.
- If you do not hear the 2nd “click”:
  - Check that the inspection window is filled with the yellow indicator.
  - If you are not sure, hold the autoinjector down for another 15 seconds to make sure the injection is complete.

**Do not** lift the autoinjector until you are sure you have completed your injection.
- You may notice a small drop of blood at the injection site. This is normal. Press a cotton ball or gauze on the area for a few moments if necessary.

**Do not** rub your injection site.

8. **Dispose of the used autoinjector**
- Dispose of the used autoinjector and needle cap according to local requirements. Ask your doctor, nurse or pharmacist for advice if necessary.
- Keep your used autoinjectors and needle caps out of the reach of children.
NUCALA (mepolizumab injection)

INSTRUCTIONS FOR USE - PRE-FILLED SAFETY SYRINGE

Administer once every four weeks

These INSTRUCTIONS FOR USE should be read together with the rest of the PATIENT MEDICATION INFORMATION in your NUCALA package. Contact your healthcare professional if you have any questions about NUCALA.

Follow these instructions on how to use the pre-filled safety syringe. Failure to follow these instructions may affect proper function of the pre-filled safety syringe. You should also receive training on how to use the pre-filled safety syringe. NUCALA pre-filled safety syringe is for use under the skin only (subcutaneous).

How to store NUCALA

- Keep refrigerated before use.
- Do not freeze.
- Keep in the carton to protect from light.
- Keep out of the sight and reach of children.
- If necessary, the pre-filled safety syringe may be kept at below 30°C, for no more than 7 days, when stored in the original carton. Throw it away if it has not been used within 7 days.
- The safety syringe must be used within 8 hours once the carton is opened. Discard if not used within 8 hours.
- Do not store it above 30°C.

Before you use NUCALA

The pre-filled safety syringe should be used only once and then discarded.
- Do not share your NUCALA pre-filled safety syringe with another person.
- Do not shake the syringe.
- Do not use the syringe if dropped onto a hard surface.
- Do not use the syringe if it appears damaged.
- Do not remove the needle cap until just before your injection.
Gather Supplies

Find a comfortable, well-lit and clean surface. Make sure you have within reach:

- NUCALA pre-filled safety syringe
- Alcohol wipe (not included)
- Gauze pad or cotton ball (not included)

**Do not** perform the injection if you do not have all these.
1. Prepare the NUCALA safety syringe

- Take the carton out of the refrigerator. Check the security seals are not broken.
- Remove the tray from the carton.
- Peel back the film cover from the tray.
- Holding the middle of the syringe, carefully take it out of the tray.
- Place the syringe on a clean, flat surface, at room temperature, away from direct sunlight and out of the reach of children.

**Do not** use the syringe if the security seal on the carton is broken.
**Do not** remove the needle cap at this stage.

2. Inspect and wait 30 minutes before use

- Check the expiry date on the label of the syringe.
- Look in the inspection window to check that the liquid is clear (free from cloudiness or particles) and colourless or pale yellow or pale brown.
- It is normal to see one or more air bubbles.
- Wait 30 minutes (and no more than 8 hours) before use.

**Do not** use if the expiry date has passed.
**Do not** warm the syringe in a microwave, hot water, or direct sunlight.
**Do not** inject if the solution looks cloudy or discoloured, or has particles.
**Do not** use the syringe if left out of the carton for more than 8 hours.
**Do not** remove the needle cap during this step

3. Choose your injection site

- You can inject NUCALA into your thighs or abdomen.
- If someone else gives you the injection, they can also use your upper arm.
- If you need more than one injection to complete your dose then leave at least 5 cm (2 inches) between each injection site.

**Do not** inject where your skin is bruised, tender, red or hard.
**Do not** inject within 5 cm (2 inches) of your navel (belly button).
4. Clean your injection site

- Wash your hands with soap and water.
- Clean your injection site by wiping the skin with an alcohol wipe and allowing the skin to air dry.

**Do not** touch your injection site again until you have finished your injection.

5. Remove the needle cap

- Remove the needle cap from the syringe by firmly pulling it straight off, extending your hand away from the needle end (as shown).
- You may need to pull the needle cap quite firmly to remove it.

**Do not** worry if you see a drop of liquid at the end of the needle. This is normal. Inject straight after removing the needle cap, and always within 5 minutes.

**Do not** let the needle touch any surface.

**Do not** touch the needle.
Do not touch the plunger at this stage, as you can accidentally push liquid out and will not receive your full dose.

Do not expel any air bubbles from the syringe.

Do not put the needle cap back onto the syringe. This could cause a needle injury.

6. Start your injection

- Use your free hand to pinch the skin around your injection site. Keep the skin pinched throughout your injection.
- Insert the entire needle into the pinched skin at a 45° angle, as shown.
- Move your thumb to the plunger and place your fingers on the white finger grip, as shown.
- Slowly push down on the plunger to inject your full dose.

7. Complete your injection

- Slowly push down on the plunger to inject your full dose.
- Slowly raise your thumb.
• Make sure the plunger is pushed all the way down, until the stopper reaches the bottom of the syringe and all of the solution is injected.
• Slowly lift your thumb up. This will allow the plunger to come up and the needle to retract (rise up) into the body of the syringe.
• Once complete, release the pinched skin.
  ○ You may notice a small drop of blood at the injection site. This is normal. Press a cotton ball or gauze on the area for a few moments if necessary.

Do not put the needle cap back onto the syringe.
Do not rub your injection site.

8. Dispose of the used syringe

• Dispose of the used syringe and needle cap according to local requirements. Ask your doctor, nurse or pharmacist for advice if necessary.
• Keep your used syringes and needle caps out of the reach of children